Pneumococcal conjugate vaccines for preventing otitis media by Fortanier, Alexandre C. et al.
  
 University of Groningen
Pneumococcal conjugate vaccines for preventing otitis media
Fortanier, Alexandre C.; Venekamp, Roderick P.; Boonacker, Chantal W. B.; Hak, Eelko;
Schilder, Anne G. M.; Sanders, Elisabeth A. M.; Damoiseaux, Roger A. M. J.
Published in:
Cochrane database of systematic reviews (Online)
DOI:
10.1002/14651858.CD001480.pub4
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Fortanier, A. C., Venekamp, R. P., Boonacker, C. W. B., Hak, E., Schilder, A. G. M., Sanders, E. A. M., &
Damoiseaux, R. A. M. J. (2014). Pneumococcal conjugate vaccines for preventing otitis media. Cochrane
database of systematic reviews (Online), (4), [001480]. https://doi.org/10.1002/14651858.CD001480.pub4
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Cochrane Database of Systematic Reviews
Pneumococcal conjugate vaccines for preventing otitis media
(Review)
Fortanier AC, Venekamp RP, Boonacker CWB, Hak E, Schilder AGM, Sanders EAM, Damoiseaux
RAMJ
Fortanier AC, Venekamp RP, Boonacker CWB, Hak E, Schilder AGM, Sanders EAM, Damoiseaux RAMJ.
Pneumococcal conjugate vaccines for preventing otitis media.
Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD001480.
DOI: 10.1002/14651858.CD001480.pub4.
www.cochranelibrary.com
Pneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
49APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
54SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
54DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
54NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
54INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iPneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Pneumococcal conjugate vaccines for preventing otitis media
Alexandre C Fortanier1, Roderick P Venekamp2, Chantal WB Boonacker1 , Eelko Hak3, Anne GM Schilder4, Elisabeth AM Sanders
5, Roger AMJ Damoiseaux1
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. 2Department of
Otorhinolaryngology & Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
3Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands. 4evidENT, Ear Institute, Faculty of
Brain Sciences, University College London, London, UK. 5Department of Pediatric Immunology and Infectious Diseases, Wilhelmina
Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands
Contact address: Roger AMJ Damoiseaux, Julius Center for Health Sciences and Primary Care, University Medical
Center Utrecht, HP: Str. 6.131, PO Box 85500, Utrecht, 3508 GA, Netherlands. R.A.M.J.Damoiseaux@umcutrecht.nl,
rdamoiseaux@hotmail.com, R.DAMOISEAUX@tiscali.nl.
Editorial group: Cochrane Acute Respiratory Infections Group.
Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 4, 2014.
Citation: Fortanier AC, Venekamp RP, Boonacker CWB, Hak E, Schilder AGM, Sanders EAM, Damoiseaux RAMJ. Pneumococcal
conjugate vaccines for preventing otitis media. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD001480. DOI:
10.1002/14651858.CD001480.pub4.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Acute otitis media (AOM) is a very common respiratory infection in early infancy and childhood. The marginal benefits of antibiotics
for AOM in low-risk populations in general, the increasing problem of bacterial resistance to antibiotics and the huge estimated direct
and indirect annual costs associated with otitis media (OM) have prompted a search for effective vaccines to prevent AOM.
Objectives
To assess the effect of pneumococcal conjugate vaccines (PCVs) in preventing AOM in children up to 12 years of age.
Search methods
We searched CENTRAL (2013, Issue 11), MEDLINE (1995 to November week 3, 2013), EMBASE (1995 to December 2013),
CINAHL (2007 to December 2013), LILACS (2007 to December 2013) and Web of Science (2007 to December 2013).
Selection criteria
Randomised controlled trials (RCTs) of PCVs to prevent AOM in children aged 12 years or younger, with a follow-up of at least six
months after vaccination.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data.
Main results
We included 11 publications of nine RCTs (n = 48,426 children, range 74 to 37,868 per study) of 7- to 11-valent PCV (with different
carrier proteins). Five trials (n = 47,108) included infants, while four trials (n = 1318) included children aged one to seven years that
were either healthy (one study, n = 264) or had a previous history of upper respiratory tract infection (URTI), including AOM. We
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judged the methodological quality of the included studies to be moderate to high. There was considerable clinical diversity between
studies in terms of study population, type of conjugate vaccine and outcome measures. We therefore refrained from pooling the results.
In three studies, the 7-valent PCV with CRM197 as carrier protein (CRM197-PCV7) administered during early infancy was associated
with a relative risk reduction (RRR) of all-cause AOM ranging from -5% in high-risk children (95% confidence interval (CI) -25% to
12%) to 7% in low-risk children (95% CI 4% to 9%). Another 7-valent PCV with the outer membrane protein complex of Neisseria
meningitidis (N. meningitidis) serogroup B as carrier protein, administered in infancy, did not reduce overall AOM episodes, while a
precursor 11-valent PCV with Haemophilus influenzae (H. influenzae) protein D as carrier protein was associated with a RRR of all-
cause AOM episodes of 34% (95% CI 21% to 44%).
A 9-valent PCV (with CRM197 carrier protein) administered in healthy toddlers was associated with a RRR of (parent-reported) OM
episodes of 17% (95%CI -2% to 33%). CRM197-PCV7 followed by 23-valent pneumococcal polysaccharide vaccination administered
after infancy in older children with a history of AOM showed no beneficial effect on first occurrence and later AOM episodes. In
a study in older children with a previously diagnosed respiratory tract infection, performed during the influenza season, a trivalent
influenza vaccine combined with placebo (TIV/placebo) led to fewer all-cause AOM episodes than vaccination with TIV and PCV7
(TIV/PCV7) when compared to hepatitis B vaccination and placebo (HBV/placebo) (RRR 71%, 95% CI 30% to 88% versus RRR
57%, 95% CI 6% to 80%, respectively) indicating that CRM197-PCV7 after infancy may even have negative effects on AOM.
Authors’ conclusions
Based on current evidence of the effects of PCVs for preventing AOM, the licensed 7-valent CRM197-PCV7 has modest beneficial
effects in healthy infants with a low baseline risk of AOM. Administering PCV7 in high-risk infants, after early infancy and in older
children with a history of AOM, appears to have no benefit in preventing further episodes. Currently, several RCTs with different
(newly licensed, multivalent) PCVs administered during early infancy are ongoing to establish their effects on AOM. Results of these
studies may provide a better understanding of the role of the newly licensed, multivalent PCVs in preventing AOM. Also the impact
on AOM of the carrier protein D, as used in certain pneumococcal vaccines, needs to be further established.
P L A I N L A N G U A G E S U M M A R Y
Vaccination against a bacterium called pneumococcus for preventing middle ear infection
Review question
We reviewed the evidence about the effect of vaccination against pneumococcus (a type of bacterium) on preventing middle ear
infections in children.
Background
Middle ear infection, or otitis media, is one of the most common respiratory infections in childhood. Infection with Streptococcus
pneumoniae (pneumococcus) is a frequent cause of middle ear infection. Vaccination against pneumococcus with pneumococcal
conjugate vaccines (PCVs) is primarily introduced to protect young children against severe pneumococcal infections, such as meningitis
and pneumonia. We wanted to discover whether vaccination with PCV also leads to fewer middle ear infections in children.
Study characteristics
This review included evidence up to 3 December 2013. Nine trials with a total of 48,426 children were included; five trials included
47,108 infants, while four trials included 1318 children at a later age, i.e. aged one to seven years, who were either healthy (one trial,
264 children) or had previous upper respiratory tract infections, including middle ear infections. All trials had a long follow-up, varying
from 6 to 40 months.
Key outcomes
When vaccinating against seven different serotypes of pneumococcus (7-valent PCV) during early infancy, the occurrence of middle
ear infections either increased by 5% or decreased by 6% to 7%. One study in infants used 11 serotypes of pneumococcus together
with a carrier protein from another bacterium (Haemophilus influenzae); this decreased the occurrence of middle ear infections by 34%.
Children with a history of middle ear infections do not seem to benefit from 7-valent PCV when immunised at an older age (after
infancy).
2Pneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Quality of the evidence
We judged the quality of the evidence for 7-valent PCV in early infancy to be high (further research is very unlikely to change our
confidence in the estimate of effect), while we judged the quality of the evidence for multivalent (more than seven different serotypes)
PCV to be moderate (further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate), as this evidence is derived from only one trial. We judged the quality of the evidence for 7-valent PCV in older children
with a history of middle ear infections to be high.
Future studies on the effects of PCV in infants, with broader serotype coverage (more than seven different serotypes), are likely to
provide more understanding of the role of PCV in preventing middle ear infections.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pneumococcal conjugate vaccine compared with control intervention for preventing acute otitis media
Patient or population: children aged 12 years or younger and a follow-up af ter vaccinat ions of at least 6 months
Settings: open populat ion
Intervention: mult ivalent PCVs
Comparison: control treatment
Outcomes VE - relative effect (95% CI)* No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Frequency of all- cause AOM
PCV7 administered in early infancy
Follow-up 6 to 42 months
RRR: -5% to 7% 42,140 (4) ⊕⊕⊕⊕
high
Results are derived f rom 1 very large
trial (Black 2000/ Fireman 2003) and 3
trials of approximately equal size (944
to 1666 part icipants) (Eskola 2001; Kilpi
2003; O’Brien 2008)
Lowest ef f icacy was found in high-risk
children (O’Brien 2008)
Frequency of all- cause AOM
PD-PCV11 administered in early in-
fancy
Follow-up 27 months
RRR 34% (21 to 44) 4968 (1) ⊕⊕⊕©
moderate
Results derived f rom 1 high-quality trial
(Prymula 2006)
Part of the ef fect may be related to the
protein D to which the polysaccharides
are conjugated in the vaccine PD-PCV11,
demonstrated to reduce non-typeable H.
influenzae by 35% (95% CI 2 to 57)
AOM incidence rate in control group was
low compared to the other studies on the
ef fect on PCV7 in infants and the absolute
risk dif f erence was small (Table 1)




RRR 17% (-2 to 33) 264 (1) ⊕⊕⊕©
moderate
Results derived f rom 1 trial of moderate
methodological quality (Dagan 2001). Un-
certainty about the ef fect size (stat ist i-







































































































Frequency of all- cause AOM
PCV7 administered in older children
with a known history of AOM
Follow-up 6 to 26 months
RRR -29% to 57% 1054 (3) ⊕⊕⊕⊕
high
Results are derived f rom 2 high-quality tri-
als (Veenhoven 2003; Van Kempen 2006)
and 1 trial of moderate methodological
quality (Jansen 2008). The 2 high-quality
trials found no benef icial ef fect of PCV
in prevent ing AOM recurrences, while the
other trial f ound PCV7/ TIV not to be su-
perior to TIV/ placebo in prevent ing AOM
during the inf luenza season
Frequency of pneumococcal
AOM
PCV7 administered in early infancy
Follow-up 6 to 42 months
RRR 20% to 34% 1233 (2) ⊕⊕⊕⊕
high
Results are derived f rom 2 high-quality




PD-PCV11 administered in early in-
fancy
Follow-up 27 months
RRR 52% (37 to 63) 281 (1) ⊕⊕⊕©
moderate
Results derived f rom 1 high-quality trial in
which myringotomy was performed in all
children (Prymula 2006)
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
*Results include both ITT and PP results; 95% CI lacking in case of mult iple studies (range of ef fect est imates presented as we ref rained f rom pooling)
AOM: acute ot it is media
CI: conf idence interval
ITT: intent ion-to-treat
OM: ot it is media
PCV: pneumococcal conjugate vaccine
PP: per-protocol
RRR: relat ive reduct ion in risk
TIV: trivalent inact ivated inf luenza vaccine






































































































B A C K G R O U N D
Description of the condition
Acute otitis media (AOM), defined as middle ear effusion accom-
panied by one or more signs of acute inflammation in the middle
ear, such as otalgia, otorrhoea, fever or irritability, is one of themost
common diseases in childhood, imposing a large burden on pub-
lic health. It has a peak incidence in six to 11-month-old infants
(Teele 1989). By the age of one year, approximately 60% of infants
have experienced at least one AOM episode and by the age of two
years up to 5% of all children have experienced recurrent episodes
of AOM, defined as three or more AOM episodes in six months or
four or more in one year (Kvaerner 1997; Teele 1989). The three
main bacterial pathogens isolated from the middle ear fluid of
children with AOM, collected before the widespread use of pneu-
mococcal conjugate vaccines (PCVs), were Streptococcus pneumo-
niae (S. pneumoniae) (25% to 39%), (non-typeable) Haemophilus
influenzae (H. influenzae) (12% to 23%) andMoraxella catarrhalis
(M. catarrhalis) (4% to 15%) (Bluestone 1992; Heikkinen 1999;
Jacobs 1998; Luotonen 1981). Recent studies have shown that
nationwide implementation of PCVs may have changed the fre-
quency of the causative otopathogens involved in AOM towards
pneumococcal serotypes not included in the vaccines and non-
typeable H. influenzae (ntHi) (Casey 2013; Coker 2010; Somech
2011; Wiertsema 2011).
Description of the intervention
The marginal benefits of antibiotics for AOM in low-risk popula-
tions (Rovers 2006; Spiro 2008; Venekamp 2013), the increasing
problem of bacterial resistance against antibiotics (Arason 1996;
Del Castillo 1998; Dagan 2000; Goossens 2007) and the high es-
timated direct and indirect annual costs associated with otitis me-
dia (OM) (Boonacker 2011; Kaplan 1997; Niemela 1999) have
prompted a search for effective vaccines to prevent AOM.
How the intervention might work
With S. pneumoniae (pneumococcus) being the prime bacterial
cause of AOM and childhood pneumonia, and one of the most
common causes of invasive bacterial disease such as meningitis,
research has focused on the prevention of pneumococcal infec-
tions with pneumococcal vaccines. Pneumococcal polysaccharide
vaccines (PPVs) have been available for decades but have been
shown to be poorly immunogenic in children below two years of
age, who are most prone to pneumococcal infections. The first
pneumococcal conjugate vaccines (PCVs), in which the pneumo-
coccal capsular serotypes are covalently conjugated to carrier pro-
teins, were developed in the 1990s and proved to be adequately
immunogenic in infants and toddlers (Dagan 1997; Eskola 1999;
Shinefield 1999). No further attention will be paid to the effect
of PPVs, which were described in a prior version of this review
(Straetemans 2003).
Why it is important to do this review
With AOM being amongst the most common diseases in early
childhood, the need for a vaccine to prevent effectively AOM is
high. Over the past decades various randomised controlled trials
(RCTs) have been performed to assess the effects of pneumococ-
cal vaccination to prevent AOM. From 2009 onwards, two mul-
tivalent PCVs (10- and 13-valent PCVs) have been licensed and
are being implemented in nationwide immunisation programmes
worldwide (WHO 2012). These new vaccines may have an in-
creased benefit in preventingAOM(Marom 2014;O’Brien2009).
As such, it is important to provide an up-to-date systematic review
on the effects of pneumococcal vaccination on preventing AOM.
This review is an update of a Cochrane review first published
in 2002 (Straetemans 2002), and updated in 2004 (Straetemans
2004) and 2009 (Jansen 2009).
O B J E C T I V E S
To assess the effect of pneumococcal conjugate vaccines (PCVs)
in preventing AOM in children up to 12 years of age.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs of PCVswith prevention of AOMas an outcome in children
aged 12 years or younger and a follow-up for at least six months.
Types of participants
Children up to 12 years of age.
Types of interventions
Multivalent PCVs.
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Types of outcome measures
Primary outcomes
Frequency of all-cause AOMepisodes defined as AOMirrespective
of causative pathogen, as we considered this to be most relevant
for children, parents and physicians.
Secondary outcomes
1. Frequency of pneumococcal AOM.
2. Frequency of pneumococcal serotype-specific AOM.
3. Frequency of recurrent AOM (defined as three or more
episodes in the last six months or four or more in the last year).
Search methods for identification of studies
Electronic searches
For this update we searched theCochraneCentral Register of Con-
trolled Trials (CENTRAL) (2013, Issue 11), which contains the
Cochrane Acute Respiratory Infections Group’s Specialised Reg-
ister; MEDLINE (1995 to November week 3, 2013); EMBASE
(1995 to December 2013); CINAHL (2007 to December 2013);
LILACS (2007 to December 2013) and Web of Science (2007 to
December 2013).
We used the following search strategy to search CENTRAL
and MEDLINE. We combined the MEDLINE search with the
Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision); Ovid format (Lefebvre 2011). We
adapted the search strategy to search EMBASE (Appendix 2),
CINAHL (Appendix 3), LILACS (Appendix 4) and Web of Sci-
ence (Appendix 5).
MEDLINE (Ovid)







8 (pneumococc* adj5 (vaccin* or conjugat* or immuni*)).tw,nm.
9 pcv*.tw,nm.
10 or/5-9
11 4 and 10
Searching other resources
To increase the yield of relevant studies we reviewed the refer-
ence lists of all studies and review articles retrieved. We imposed
no language restrictions on the searches. We checked Clinical-
Trials.gov (http://clinicaltrials.gov/) and WHO ICTRP (http://
www.who.int/trialsearch) for completed and ongoing trials (3 De-
cember 2013).
Data collection and analysis
Selection of studies
Three review authors (ACF, RPV, CWB) independently screened
titles and abstracts obtained from the database searches and re-
viewed the full text of the potentially relevant titles and abstracts
against the inclusion criteria. We resolved disagreements by dis-
cussion.
Data extraction and management
Two review authors (ACF, RPV) independently extracted data
from the included studies. We resolved disagreements by discus-
sion.
Assessment of risk of bias in included studies
Two review authors (ACF, RPV) independently assessed the
methodological quality of the included trials. We resolved any dis-
agreements by discussion. We assessed the methodological qual-
ity of included studies using the ’Risk of bias’ tool as described
in Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We judged the following domains
as high, low or unclear risk of bias: random sequence generation
(selection bias), concealment of allocation (selection bias), blind-
ing of participants and personnel (performance bias), blinding of
outcome assessment (detection bias), incomplete outcome data
(attrition bias), selective reporting (reporting bias) and other bias.
We presented the results of the ’Risk of bias’ assessment in a ’Risk
of bias’ graph (Figure 1) and a ’Risk of bias’ summary (Figure 2).
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Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Measures of treatment effect
For both our primary and secondary outcomes we extracted the
relative risks and their accompanying 95% CIs. Vaccine efficacy
was estimated as 1 minus the relative risk (relative risk reduction
(RRR)).
Unit of analysis issues
We included all types of RCTs. In case of cluster-randomised tri-
als, we considered potential differences between the intervention
effects being estimated.
Dealing with missing data
Weprimarily presented data based on the intention-to-treat (ITT)
principle, i.e. all data were analysed in the group to which the
participants were originally allocated. As a secondary analysis, we
presented data based on the per-protocol analysis. For each trial,
we determined the number of missing data and whether the au-
thors took duration of follow-up (and censoring) of individual
participants into account in their statistical analyses.
Assessment of heterogeneity
Meta-analysis by pooling the results of the different trials is only
useful and justified when trials show satisfactory clinical homo-
geneity in terms of study population, setting, intervention and
outcome measures. We assessed clinical diversity between trials
by reviewing the differences across trials. There was considerable
clinical diversity between trials. First, there were differences in the
timing of PCV administration, i.e. trials administering PCV dur-
ing infancy and trials administering PCV later in life. As such,
study populations varied from healthy infants to those at high risk
of AOM. Second, the number of pneumococcal serotypes present
in the vaccines, the type of conjugate method used and co-admin-
istration of non-bacterial vaccines differed across trials. For exam-
ple, the protein D carrier, as used in one trial assessing the effect
of PD-PCV11 (Prymula 2006), has been shown to be beneficial
in reducing AOM caused by non-typeableH. influenzae (ntHi)
(Prymula 2006), and as such may have an impact on all-cause
AOMbeyond pneumococcal AOM. Furthermore, co-administra-
tion of a trivalent flu vaccine with CRM197-PCV7, as used in
another trial (Jansen 2008), may have substantial impact on all-
cause AOM. Finally, large differences in outcome assessments and
AOM definitions were observed, varying from ’passive’ (chart re-
view at end of the trial) versus ’active’ (parents were instructed to
visit a physician in case of AOM symptoms) outcome assessments.
As a consequence, AOM incidence in the control groups varied
widely across the studies administering PCV during infancy, i.e.
from 0.13 to 1.3 episodes per person-year. Therefore, we decided
that a meta-analysis was not appropriate.
Assessment of reporting biases
For each study, we searched the Internet and ClinicalTrials.gov
(http://clinicaltrials.gov/) for available study protocols to deter-
mine whether all a priori defined outcomes have been reported in
the publications.
Data synthesis
As we refrained from pooling (see Assessment of heterogeneity
section), we reported the effect estimates as presented by the in-
dividual trials. Where possible we reported the incidences of the
various outcomes in the study arms together with the vaccine ef-
ficacy estimates, with 95% confidence intervals (CIs). However,
due to limitations of the data, we reported alternative statistical
measures in some instances.
We will briefly describe the methods we would have used if we
had pooled the results. The generalised Cox proportional hazard
method proposed byAndersen 1982 is regarded as themost appro-
priate to assess the effect of PCVs on AOM (Jahn-Eimermacher
2007). Under the assumption that the hazard rate is proportional
between both groups over time and that the risk of AOM is not af-
fected by previous episodes (although this assumption is not true),
this model takes all available information into account; that is, all
episodes (also the recurrent ones), differences in individual patient
follow-up time and time until a case of AOM (Jahn-Eimermacher
2007). However, information on individual follow-up time until
the first, second, third, etc. case of AOM is hard to obtain for each
study to be included in the meta-analysis. Poisson regression is
based on the assumption of a constant risk of AOM over time and
that this risk is not affected by previous episodes of AOM. This
method only requires the total follow-up time and total number of
episodes and appears therefore a more feasible method for meta-
analysis. Furthermore, Poisson regression seems not to be affected
by the deviation from a constant risk over time, having very sim-
ilar results for the effect of PCVs on AOM to the Anderson-Gill
approach (Jahn-Eimermacher 2007). For Poisson regression, the
treatment effect is measured as a rate ratio defined as follows: (total
AOM episodes in pneumococcal vaccination group divided by the
number of children in the pneumococcal vaccination group mul-
tiplied by the follow-up time in months) divided by (total AOM
episodes in control group divided by the number of children in
the control group multiplied by the follow-up time in months)
(McCullagh 1989).
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Subgroup analysis and investigation of heterogeneity
Since the effect of PCVs on AOMmay be influenced by the age at
which the PCV was administered and the occurrence of previous
AOM episodes, we described the studies accordingly, that is, those
with vaccination in early infancy versus those with vaccination
later in childhood.
Sensitivity analysis
As mentioned, the clinical diversity between the studies was large
and thereforewe decidednot tometa-analyse the trials nor conduct
a sensitivity analysis on, for example: risk status (age, number
of previous episodes), outcome measurement or adjustments for
clustering in the case of a cluster-randomised trial.
R E S U L T S
Description of studies
See the Characteristics of included studies, Characteristics of
excluded studies and Characteristics of ongoing studies tables.
Results of the search
This is an update of a Cochrane review first published in 2002
(Straetemans 2002) and updated in 2004 (Straetemans 2004) and
2009 (Jansen 2009). In the 2009 review, which included studies
up toNovember 2007, eight publicationswere found eligible, con-
cerning a total of seven RCTs (Black 2000/Fireman 2003; Dagan
2001; Eskola 2001; Kilpi 2003; Prymula 2006; Van Kempen
2006; Veenhoven 2003). The studies of Eskola 2001 and Kilpi
2003 are part of the FinOM Vaccine Trial (three parallel-group
trials using the same control group (hepatitis B vaccine) but two
different treatment groups, each with a different type of 7-valent
pneumococcal conjugate vaccine) and we therefore regarded them
as two ’separate’ trials in this review.
With the updated search (November 2007 to December 2013)
we retrieved 171 records. Removing duplicates left 165 records.
After screening titles and abstracts, we identified seven potentially
eligible studies. After obtaining the full text of these papers, we
excluded two studies as they studied the effect of pneumococ-
cal vaccination on either otitis media with effusion (OME) (Le
2007) or suppurative otitis media (Roy 2011). Furthermore, one
RCT studying the effect of PCV on (recurrent) AOM was ex-
cluded as the children in the control group did not receive any type
of vaccination (PCV versus no vaccination), while for outcome
assessment non-blinded parents were instructed to visit the ear,
nose and throat (ENT) department whenever they suspected an
episode of AOM; the parental threshold to consult ENT depart-
ments may be lower in children allocated to the control treatment
(no vaccination) than in those allocated to PCV, which may have
introduced (detection) bias (Gisselsson Solen 2011). Finally, one
trial was excluded (Jokinen 2012), as this study was a re-analy-
sis of the Eskola 2001 study and did not include new outcome
data useful to this review. This left three new publications eligi-
ble for inclusion (Jansen 2008; O’Brien 2008; Palmu 2009). One
study (Palmu 2009) was an additional analysis of the previously
included Eskola 2001 study.We did not identify any additional el-
igible trials after scanning the reference lists of the full-text papers
and relevant systematic reviews. In searchingClinicalTrials.gov, we
identified five ongoing RCTs (NCT00466947; NCT00861380;
NCT01545375; NCT01735084; NCT01174849) (see also the
Characteristics of ongoing studies table).
Included studies
The 11 included trials in this review originate from nine RCTs in
total: (1) Black 2000/Fireman 2003; (2) Dagan 2001; (3) Eskola
2001/Palmu 2009; (4) Jansen 2008; (5) Kilpi 2003; (6) O’Brien
2008; (7) Prymula 2006; (8) Van Kempen 2006; (9) Veenhoven
2003.
Study designs
Of these trials, eight were standard, individually randomised trials,
while one trial was a cluster-randomised trial (O’Brien 2008).
Study populations (early infancy versus later in life)
Five trials (Black 2000/Fireman 2003; Eskola 2001/Palmu 2009;
Kilpi 2003; O’Brien 2008; Prymula 2006) included healthy in-
fants and studied the effect of PCV administered in early infancy
(first dose before the age of 12 months) on otitis media (OM),
while the other four trials (Dagan 2001; Jansen 2008;VanKempen
2006; Veenhoven 2003) assessed the effects of PCV administered
at a later age on OM in either healthy infants (Dagan 2001), or
in children with a known history of respiratory disease, including
OM (Jansen 2008; Van Kempen 2006; Veenhoven 2003).
Interventions (type of PCV used)
In all nine RCTs the control group received a control vaccine. In
six trials the 7-valent PCV containing the polysaccharides of seven
serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) coupled to the car-
rier protein CRM197 (a non-toxic mutant of diphtheria toxin)
(CRM197-PCV7) was used as the intervention (Black 2000/
Fireman 2003; Eskola 2001/Palmu 2009; Jansen 2008; O’Brien
2008; Van Kempen 2006; Veenhoven 2003). In two of these
studies a booster dose with 23-valent PPV (containing capsular
polysaccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V,
10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and
33F) was given to all children (Van Kempen 2006; Veenhoven
2003), while in one trial CRM197-PCV7 was administered with
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a trivalent inactivated influenza vaccine (TIV) (Jansen 2008). The
other three studies (Dagan 2001; Kilpi 2003; Prymula 2006) used
different interventions, i.e. a 9-valent PCV containing the cap-
sular polysaccharides of serotypes 1 and 5 besides those included
in CRM197-PCV7, conjugated to CRM197 (CRM197-PCV9)
(Dagan 2001), a 7-valent PCVwith the outer membrane complex
of N. meningitidis serogroup B as protein carrier (OMPC-PCV7)
(Kilpi 2003) and a subgroup of these children received a PPV23
as a booster dose and an 11-valent PCV containing the capsular
polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F
and 23F, conjugated to protein D, which is a surface lipoprotein
of H. influenzae (PD-PCV11) (Prymula 2006).
Outcomes
Five studies applied a standardised diagnosis of AOM (Eskola
2001/Palmu2009;Kilpi 2003; Prymula 2006;VanKempen2006;
Veenhoven 2003), one study used standardised AOM registra-
tion forms to be completed by GPs (Jansen 2008), whereas in
two studies AOM episodes were extracted from a computerised
data source containing all visits registered by physicians (Black
2000/Fireman 2003; O’Brien 2008). Another study assessed par-
ent-reported AOM episodes (Dagan 2001). Six studies addition-
ally assessed the effect of PCVs on (serotype-specific) pneumococ-
cal AOM (Black 2000/Fireman 2003; Eskola 2001; Kilpi 2003;
O’Brien 2008; Prymula 2006; Veenhoven 2003). Three studies
cultured middle ear fluid from all AOM episodes (Eskola 2001;
Kilpi 2003; Prymula 2006), whereas one study only cultured it
from the first AOM episode by myringotomy or from sponta-
neously draining ears (Veenhoven 2003). Two other studies as-
sessed the effect on reported cultures that were taken in cases of
spontaneously draining ears (Black 2000/Fireman 2003; O’Brien
2008). Three studies reported on the effects of PCVs on recurrent
AOM (Black 2000/Fireman 2003; Eskola 2001; Prymula 2006).
Three of the included studies had all types of OM (including but
not exclusively AOM) as an outcome (Black 2000/Fireman 2003;
Dagan 2001; O’Brien 2008). Since the effect of PCVs on AOM
may be influenced by the age at which the PCV was administered
and the occurrence of previous episodes of AOM, we will further
describe the studies accordingly; that is, those with vaccination in
infancy versus those vaccinated later in childhood.
PCV administered in early infancy (first dose before the age
of 12 months)
In the Northern California Kaiser Permanente (NCKP) trial
(Black 2000/Fireman 2003), the Finnish Otitis Media (FinOM)
trial (Eskola 2001/Palmu 2009) and the trial among Navajo and
White Mountain Apache children (O’Brien 2008), the treatment
group was administered CRM197-PCV7, at the age of two, four
and six months and 12 to 15 months. In the NCKP trial (Black
2000/Fireman 2003), infants were enrolled over a period of al-
most three years and had a follow-up time varying from about
eightmonths to 30months (Black 2000) and 42months (Fireman
2003), respectively. The trial was originally designed to investi-
gate the effect of CRM197-PCV7 on invasive pneumococcal dis-
ease, with OM as a secondary outcome. Clinical diagnoses of OM
were obtained from a computerised database collecting depart-
ment-specific diagnosis checklists routinely marked by emergency
physicians and paediatricians in the NCKP population. All clin-
ical diagnoses of ’otitis media’, ’otitis media, acute’, ’middle ear
effusion’, ’otitis media, serous’ or ’otitis media with effusion’ were
included.
The FinOM trial primarily aimed to assess the effect of CRM197-
PCV7onAOM(Eskola 2001/Palmu2009). Infants were followed
until the age of 24 months and parents were encouraged to bring
their child to the study clinic (established specifically for the pur-
pose) for evaluation of symptoms suggesting respiratory infection
or AOM.The diagnosis of AOMwas standardised. In recent years,
an additional analysis was performed as part of the Eskola 2001
trial, including pneumolysin-PCR positive AOM (Palmu 2009).
The trial among Navajo and White Mountain Apache children
was a cluster-randomised trial primarily aiming to assess the safety
and efficacy of CRM197-PCV7 on invasive pneumococcal disease
(O’Brien 2003). These children have some of the highest rates of
invasive pneumococcal disease and otitis media in the world. Clin-
ical and culture-proven OM were secondary outcomes measured
in this trial and were assessed, at trial completion, by retrospec-
tive chart review. OM visits, as in every visit made by the study
children through to two years of age and documented by their
treating physician, were evaluated. An OM visit was defined as a
visit for ’otitis media’, ’acute otitis media’, ’bilateral OM’, ’chronic
OM’, ’OMwith perforation’, ’otorrhoea’, ’pressure equalising tube
placement’, ’perforation tympanic membrane’, ’serous OM’ and
’bullous myringitis’. Further sub-categorisation was performed on
AOM (either ’acute otitis media’ or ’bilateral otitis media’), severe
episodes, number of medical visits and pressure equalising tube
placement.
Kilpi 2003 describes another part of the FinOM trial in which the
index group was administered another 7-valent PCV, containing
capsular polysaccharides of the same seven serotypes as used in the
Eskola 2001 study, i.e. OMPC-PCV7. Additionally, 22% of the
children assigned to OMPC-PCV7 received PPV23 at the age of
12 months instead of a fourth OMPC-PCV7 dose. The follow-
up and outcome measure was similar to Eskola 2001.
Finally, in Prymula 2006 (POET trial), an 11-valent PCV was
administered at the ages of three, four, five months and 12 to
15 months, conjugated to protein D (PD-PCV11). Follow-up
continued until the age of 24 to 27 months. The primary aim of
the trial was to assess the effect on AOM and parents were advised
to consult their paediatrician if their child was sick, had ear pain
or had spontaneous ear discharge. The diagnosis of AOM was
standardised.
PCV administered at a later age (first dose administered
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after 12 months of age)
Dagan 2001 assessed the effect of CRM197-PCV9 on AOM in
healthy day-care attendees aged 12 to 35 months. The vaccine was
administered twice in 12- to 17-month-olds and once in 18- to
35-month-olds. The study was undertaken to examine the effect
on respiratory infections. In 18 encounters during the two-year
follow-up period that started one month after complete immuni-
sation, parents were questioned about illness episodes, including
OM episodes. The OM diagnosis was not physician-confirmed
and not standardised.
Van Kempen 2006 and Veenhoven 2003 assessed the effect of
pneumococcal vaccination on AOM in children aged one to seven
years with a history of at least two AOM episodes in the year
prior to study entry. CRM197-PCV7 was administered twice in
one to two year-olds and once in two to seven year-olds fol-
lowed by PPV23 six to seven months later. Children with un-
derlying illnesses, including immuno-compromising conditions,
were excluded. Both studies had a similar design and were con-
ducted in parallel, but were analysed separately due to differences
in study population (children included in Van Kempen 2006 had
a more severe history of AOM and more frequent tympanostomy
tube placement prior to study entry). Follow-up lasted about 24
months. Parents were instructed to visit the study clinics or their
family physician, otolaryngologists or paediatrician for assessment
in case of symptoms suggesting AOM. Physicians registered signs
and symptoms of every AOM episode on standard registration
forms. The diagnosis of AOM was standardised.
In Jansen 2008, children aged between 18 and 72 months were
randomly assigned in blocks of three in a 1:1:1 ratio to either
(1) two doses of CRM197-PCV7 (six months apart) administered
together with a trivalent inactivated influenza vaccine (TIV), (2)
TIV plus placebo or (3) hepatitis B virus vaccine plus placebo.
The main outcome measure was febrile respiratory tract infections
including AOMduring the influenza season. All children were eli-
gible if they had a previous history of physician-diagnosed respira-
tory tract infections (RTI). This history included ’acute otitis me-
dia’, ’cough’, acute upper RTI’, ’sinusitis’, ’acute tonsillitis’, ’acute
laryngitis/tracheitis’, ’acute bronchitis/bronchiolitis’, ’influenza’,
’pneumonia’, ’pleurisy/pleural effusion’ and ’other respiratory in-
fections’, all recorded according to the International Classification
of Primary Care (ICPC). Each parent was instructed to keep a
daily diary, recording signs or symptoms associated with RTI that
began 14 days after the second dose and continued for six to 18
months (depending on year of inclusion). The parent was also in-
structed to measure the child’s body temperature with a validated
tympanic thermometer provided by the study centre. All GP visits
were recorded as well and the GP was instructed to complete a
form including diagnosis and treatment.
Excluded studies
Four studies were excluded for various reasons (Gisselsson Solen
2011; Jokinen 2012; Le 2007; Roy 2011) (see also Characteristics
of excluded studies table).
Risk of bias in included studies
We judged the methodological quality of the included studies to
be moderate to high. For further details on the risk of bias in
included studies see the ’Risk of bias’ graph (Figure 1) and ’Risk
of bias’ summary (Figure 2).
Allocation
Concealment of allocation was adequately described in six of the
nine included trials, while in the other three trials it was unclear
due to insufficient information (Black 2000/Fireman 2003; Jansen
2008; Veenhoven 2003). We judged random sequence generation
to be adequate in five of the nine trials, while in four trials insuf-
ficient information was provided on the method of random se-
quence generation used (Black 2000/Fireman 2003; Dagan 2001;
Jansen 2008; Van Kempen 2006).
Blinding
Authors of all studies indicated that the studies were double-
blinded, but for two of the nine trials insufficient information was
provided on how blinding was performed (Black 2000/Fireman
2003; Prymula 2006).
Incomplete outcome data
Overall, we judged the risk of bias due to incomplete outcome data
to be low. In the Fireman 2003 study (extension of Black 2000),
we judged the risk of attrition bias to be high, as 27% in the PCV
group and 26% in the control group did not stay in the Kaiser
Permanente healthcare database to the end of follow-up (April
1999), while missing data were either substantial or unclear in two
trials (Jansen 2008; Palmu 2009), and in one trial the distribution
across treatment groups of those who were not included in the
primary efficacy analysis was unclear (O’Brien 2008).
Almost all trials did take duration of follow-up of individuals into
account by using either the generalised Cox proportional hazard
method (Black 2000/Fireman 2003; Eskola 2001; Kilpi 2003;
Prymula 2006; Van Kempen 2006; Veenhoven 2003), or Poisson
regression analyses (Jansen 2008; O’Brien 2008). One trial used a
Chi2 test to compare rates of AOM, which is considered subopti-
mal (Dagan 2001).
Selective reporting
In three trials, we judged the risk of reporting bias to be low
as prespecified (primary and secondary) outcomes were listed in
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ClinicalTrials.gov (Jansen 2008; O’Brien 2008; Prymula 2006).
O’Brien 2008 used a subset of the 4476 children that were in-
cluded in the cluster-randomised trial to estimate the efficacy of
PCV on the main outcome of the trial, i.e. invasive pneumococ-
cal disease for a retrospective chart review on OM. Of the 4476
children that were included in the main study (O’Brien 2003),
944 were randomly selected and 856 met the chart review crite-
ria (O’Brien 2008). In four trials no study protocol was identi-
fied (Black 2000/Fireman 2003; Dagan 2001; Van Kempen 2006;
Veenhoven 2003), while in two trials the study protocol was up-
loaded at ClinicalTrials.gov but after the completion of the study
(Eskola 2001/Palmu 2009; Kilpi 2003).
Other potential sources of bias
In four trials we detected no other potential sources of bias (Dagan
2001; Eskola 2001/Palmu 2009; Van Kempen 2006; Veenhoven
2003). In three trials study enrolment was stopped as a result
of interim analyses (Black 2000/Fireman 2003; O’Brien 2008;
Prymula 2006). These interim analyses were prespecified and per-
formed by independent data safety monitoring boards; we there-
fore judged the risk of bias as low. In one trial a sample of the chil-
dren (22%) assigned to OMPC-PCV7 received PPV23 at the age
of 12 months instead of a fourth OMPC-PCV7 dose. However, it
was unclear how it was known that only those particular children
should receive that intervention. Moreover, in one trial PCV was
administered together with a influenza vaccine (CRM197-PCV7/
TIV) (Jansen 2008). As such, it is not possible to determine the
effect of PCV only in this study.
Effects of interventions
See: Summary of findings for the main comparison
The main results are described in Summary of findings for the
main comparison.
In total, we included nine trials with 48,426 children, ranging
from 74 to 37,868 participants per study. Five trials included in-
fants who received primary vaccinations before six months of age
(47,108 participants in total) (Black 2000/Fireman 2003; Eskola
2001/Palmu 2009; Kilpi 2003; O’Brien 2008; Prymula 2006);
one study included day-care attendees aged 12 to 35 months (264
participants) (Dagan 2001), two trials included one to seven year-
olds with a history of acute otitis media (AOM) (457 participants)
(Van Kempen 2006; Veenhoven 2003), and one trial included
children aged 18 to 72 months with a previously diagnosed respi-
ratory tract infection (RTI) (597 participants) (Jansen 2008).
Wepresent the results of the individual trials as reported in the pub-
lishedpapers sincemeta-analysiswas inappropriate due to substan-
tial differences between studies. Therefore, the statistical methods
by which the data were analysed in each study are briefly assessed.
Black 2000/Fireman 2003, Eskola 2001, Kilpi 2003, Prymula
2006, Van Kempen 2006 and Veenhoven 2003 all used the gen-
eralised Cox proportional hazard method proposed by Andersen
1982, currently regarded as the most optimal for analysing this
kind of data (see Data synthesis). Dagan 2001 compared rates
of AOM, but rather than comparing them by Poisson regression
(which would presumably yield results similar to those obtained
with the Anderson approach), the Chi2 test was used, which is
suboptimal for comparing rates. Jansen 2008 used Poisson regres-
sion to compare rates of AOM, accounting for the potential de-
pendency of observations between individuals. O’Brien 2008 was
a cluster-randomised trial. The incidence rate ratio was calculated
with a Poisson regression with sandwich variance estimation to
account for within-community correlation.
Effect estimates of pneumococcal conjugate vaccines (PCVs) on
all AOM episodes, pneumococcal AOM and recurrent AOM are
summarised in Table 1, Table 2 and Table 3, respectively.
Primary outcome
1. Frequency of all-cause AOM episodes (defined as AOM
irrespective of causative pathogen)
Effect of PCV administered in early infancy
CRM197-PCV7 reduced overall AOM episodes by -5% in high-
risk children to 6% in low-risk children in intention-to-treat (ITT)
analyses andby 0% inhigh-risk children to 7% in low-risk children
in per-protocol analyses (Black 2000/Fireman 2003; Eskola 2001;
O’Brien 2008), whereas OMPC-PCV7 appeared to have no effect
on overall AOM episodes (Kilpi 2003). In a per-protocol analysis,
PD-PCV11 led to a 34% (95% confidence interval (CI) 21%
to 44%) relative reduction in AOM episodes (Prymula 2006).
However, the AOM incidence rate in the control group was low
compared to the other studies and the absolute risk difference was
small (Table 1).
Effect of PCV administered at a later age
In per-protocol analyses, CRM197-PCV9 administered in healthy
12- to 35-month-olds reduced overall otitis media (OM) episodes
by 17%(Dagan 2001), whileCRM197-PCV7 followedbyPPV23
in one to seven-year-olds with a history of AOM did not reduce
the occurrence of further AOM episodes (Van Kempen 2006;
Veenhoven 2003). CRM197-PCV7 administered together with a
trivalent influenza vaccine (CRM197-PCV7/TIV) reduced overall
AOM episodes by 57% (95% CI 6% to 80%) in per-protocol
analysis (Jansen 2008), as compared to hepatitis B (HBV)/placebo
vaccination. However, the vaccine efficacy of trivalent influenza
vaccine (TIV)/placebo, as compared to HBV/placebo, on overall
AOM, appeared to be even larger, i.e. 71% (95%CI 30% to 88%).
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Secondary outcomes
1. Frequency of pneumococcal AOM
Effect of PCV administered in early infancy
The efficacy of PCVs for pneumococcal AOM varied from 25%
forOMPC-PCV7 (Kilpi 2003), 20% to 34% forCRM197-PCV7
(Eskola 2001/Palmu 2009), to 52% for PD-PCV11 (Prymula
2006). CRM197-PCV7 and PD-PCV11 also seemed to reduce
AOM caused by the so-called cross-reactive serotypes which are
non-vaccine serotypes with a serogroup that is included in the
vaccine (Eskola 2001; Prymula 2006), while OMPC-PCV7 failed
to show cross-protection (Kilpi 2003). Although not statistically
significant, CRM197-PCV7 and OMPC-PCV7 were associated
with an increase in non-vaccine-type AOM (replacement) (Eskola
2001; Kilpi 2003) and H. influenzae AOM, while PD-PCV11
did not show pneumococcal replacement and showed a vaccine
efficacy of 35% against AOM caused by H. influenzae (Prymula
2006).
Effect of PCV administered at a later age
Only one study reported the effect of CRM197-PCV7 followed by
PPV23 on pneumococcal AOM (Veenhoven 2003). In per-pro-
tocol analysis, pneumococcal AOM was reduced by 34%, while
non-vaccine-type AOM was reduced by 21%, although none of
the estimates was statistically significant (because of small num-
bers).
2. Frequency of pneumococcal serotype-specific AOM
Effect of PCV administered in early infancy
The effect of CRM197-PCV7 on vaccine-type pneumococcal
AOM varied from 54% to 65% in ITT analyses (Black 2000/
Fireman 2003; Eskola 2001; O’Brien 2008), and from 57% to
67% in per-protocol analyses (Black 2000/Fireman 2003; Eskola
2001). In per-protocol analyses, OMPC-PCV7 appeared to re-
duce vaccine-type AOM by 56% (Kilpi 2003), while PD-PCV11
led to a 58% relative reduction in vaccine-type AOM (Prymula
2006).
Effect of PCV administered at a later age
In per-protocol analysis, CRM197-PCV7 followed by PPV23 re-
duced pneumococcal serotype-specific AOMby a statistically non-
significant 52% (Veenhoven 2003). None of the other trials re-
ported on pneumococcal (serotype-specific) AOM.
3. Frequency of recurrent AOM (defined as three or more
episodes in the last six months or four or more in the last
year)
Effect of PCV administered in early infancy
CRM197-PCV7 seemed to reduce recurrent AOMby 9% to 10%
in ITTanalyses (Black 2000/Fireman 2003; Eskola 2001), whereas
the administration of PD-PCV11was associatedwith a statistically
non-significant decrease of 56% in recurrent AOMin per-protocol
analysis (Prymula 2006).
Effect of PCV administered at a later age
None of the four trials in older children reported the effect of PCV
on recurrent AOM.
D I S C U S S I O N
Summary of main results
Clinical diversity between the nine included randomised con-
trolled trials (RCTs), in terms of study population, number of
pneumococcal serotypes present in the vaccines, type of conjugate
methodused, co-administration of non-bacterial vaccines andout-
come measures, was considerable and we therefore did not pool
results. The main findings are summarised in the Summary of
findings for the main comparison.
Based on current evidence of the effects of pneumococcal conju-
gate vaccines (PCVs) for preventing acute otitis media (AOM),
the licensed 7-valent PCV has modest beneficial effects in healthy
infants; in the studies in healthy infants, the licensed CRM197-
PCV7 was associated with a relative risk reduction (RRR) of over-
all AOM of -5% (in high-risk children) to 7% (in low-risk chil-
dren) and OMPC-PCV7 did not reduce overall AOM episodes.
PD-PCV11 showed a large reduction in all-cause AOM episodes,
i.e. 34%, compared to the PCV7 studies. In healthy toddlers,
CRM197-PCV9 was associated with a non-significant RRR of
17% of parent-reported OM episodes. Administering PCV7 in
older childrenwith a history of AOMappears to have no beneficial
effect on preventing further AOM episodes.
In infants, PCV led to a substantial reduction in AOM caused
by S. pneumoniae (RRR ranging from 20% to 52%). This bene-
ficial effect seems to be mainly driven by the large effect of PCV
on vaccine-type pneumococcal AOM (RRR ranging from 54%
to 67%). In contrast, no or even a negative contribution of PCV
was observed for non-vaccine-type pneumococcal AOM (RRR
ranging from -33% to 9%). For PCV7, there was a tendency to-
ward replacement disease by non-vaccine pneumococci as well as
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by other otopathogens, such as H. influenzae. OMPC-PCV7 ap-
peared to increase the proportion of AOMcaused byM. catarrhalis
(Kilpi 2003). This means that while PCVs are effective against
vaccine-serotype pneumococcal AOM, there is high potential for
replacement by other pathogens. Although we are confident in
the effect estimate for PCV7 administered in infancy on all-cause
AOM and pneumococcal AOM, uncertainty exists about the ef-
fect of conjugate vaccines that include more than seven pneumo-
coccal serotypes and the impact of replacement by non-vaccine-
type pneumococci or other otopathogens (Summary of findings
for the main comparison).
The large effect of PD-PCV11 on all-cause AOM found in the
trial of Prymula 2006 may not be solely explained by the four
additional serotypes covered by PD-PCV11 compared to PCV7.
Part of the effect might be related to the protein D, which has
the potential to provide protection against H. influenzae strains
causing AOM (Forsgren 2008), or may be secondary to the pre-
vention of pneumococcal AOM in the first place with ntHi as a
pathogen more frequently observed in previously inflamed mid-
dle ears (Dagan 2013; Kaur 2013). Furthermore, Prymula 2006
used a stringent outcome definition for AOM (children diagnosed
with AOM by the paediatrician were subsequently referred to the
otorhinolaryngologist for confirmation of diagnosis), which may
have contributed to the low AOM incidence rate observed in
Prymula 2006; this is about 10 times lower than the incidence
reported by other studies in infancy. It might be that in Prymula
2006 more severe episodes of AOM were identified and conse-
quently the effect may only apply to these more severe episodes.
The case definition potentially also introduced a different selec-
tion of pathogens as early findings suggest that S. pneumoniae was
associated with more severe episodes (Howie 1970). However, a
subsequent post hoc analysis of Eskola 2001, using a case defini-
tion of AOM very close to the Prymula 2006 definition, showed
only a slight impact on the vaccine efficacy estimates compared to
the original case definitions (Palmu 2008).
The effect of a multivalent PCV, i.e. CRM197-PCV9, on AOM
was evaluated in healthy toddlers attending day-care (Dagan
2001). As such, the effect of PCV9 in early life remains uncertain.
In toddlers, PCV9 led to a non-statistically significant RRR of all-
cause AOM of 17%. However, this result should be interpreted
with caution as the outcome measure (parent-reported AOM) and
the statistics were suboptimal.
In AOM there is a high potential for replacement by other
pathogens that are common colonisers of the nasopharynx.
CRM197-PCV7 is known to affect nasopharyngeal carriage of
pneumococci, with a shift from vaccine-type pneumococci to
non-vaccine-type pneumococci and other bacteria that may have
pathogenic potential (Block 2006; Casey 2013; Coker 2010;
Eskola 2001; Obaro 1996; Somech 2011; Veenhoven 2003;
Wiertsema 2011). Nasopharyngeal carriage results from a recent
RCT with a commercially available 10-valent protein D pneu-
mococcal conjugate vaccine (PD-PCV10) show similar bacterial
colonisation patterns of vaccine-type and non-vaccine-type pneu-
mococci (H. influenzae,M. catarrhalis and Staphylococcus aureus
(S. aureus)) to CRM197-PCV7 in healthy Dutch children up to
two years of age (Van den Bergh 2013). The middle ear is directly
connected to the nasopharynx and by lowering the carriage of vac-
cine-type pneumococci, a niche is created for other bacteria with
a pathogenic potential (Block 2006; Veenhoven 2003; Veenhoven
2004). Future studiesmay providemore precise information about
the extent and impact of such replacement in AOMwhen admin-
istering conjugate vaccines that include more than seven pneumo-
coccal serotypes.
Overall completeness and applicability of
evidence
The nine RCTs included in this review on the effect of PCV on
AOM in children show large heterogeneity regarding study de-
sign (standard, individually randomised trials versus group ran-
domised trial), population (age of administration of PCV and
baseline risk of AOM), intervention (vaccine valency (7-/9-/11-
valent vaccines), carrier protein (CRM197, OMPC or PD), pres-
ence or absence of additional booster immunisation with PCV
or PPV23, co-administration of non-bacterial vaccines and out-
come assessment and definition (active surveillance for standard-
ised physician-diagnosed AOM, passive collection of diagnoses of
AOMor parent-reported AOM). Furthermore, in the infant stud-
ies on AOM focusing on bacteriology (Eskola 2001; Kilpi 2003;
Prymula 2006), the control groups varied markedly in the propor-
tions of S. pneumoniae,H. influenzae andM. catarrhalis in middle
ear fluid, possibly related to time and geographic region as well
as case definition, which will affect the result of all-cause AOM
episodes prevented by pneumococcal vaccines. Additionally, three
studies included older otitis-prone children, so the intervention
was aimed at secondary or even tertiary prevention and not pri-
mary prevention (Jansen 2008; Van Kempen 2006; Veenhoven
2003). The reduced efficacy of CRM197-PCV7 in children al-
ready with a history of AOM may be explained by an increased
susceptibility to subsequent infections, not only with non-vaccine-
type pneumococci but also other nasopharyngeal colonisers, due
to ’damage’ already suffered by the middle ear mucosa caused by
priorAOM(Veenhoven 2003). Another explanation, although de-
bated, could be the non-protective, impaired antibody responses of
childrenwho are otitis-prone (Pichichero 2013;Wiertsema 2012).
Thus, it appears that the age at which PCV is administered, a
history of AOM episodes, or both, modifies the effect of PCV on
AOM, despite the fact that age alone could not be identified as a
statistically significant effect modifier (Fireman 2003; Veenhoven
2003).
Quality of the evidence
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We judged the methodological quality of the included studies to
be moderate to high. Although we were not able to pool the results
of the separate trials due to substantial clinical diversity, the overall
results were consistent.
Potential biases in the review process
In this review, we strictly adhered to the prespecified review pro-
tocol. Three review authors independently searched all relevant
electronic databases by using a search syntax comprising all rele-
vant synonyms for PCV and AOM. Additionally, we performed
a broad Internet search to identify potentially relevant articles. To
increase the yield of relevant studies, we reviewed the reference lists
of all identified studies and systematic reviews or meta-analyses.
Agreements and disagreements with other
studies or reviews
Our main findings are in agreement with two other systematic
reviews on the effect of PCV in children, indicating that PCV
may provide some protection against otitis media, but that other
factors could also have contributed to the observed effect estimates
(Pavia 2009; Taylor 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The prevention of invasive pneumococcal disease has been the pri-
mary reason for many Western countries to introduce pneumo-
coccal conjugate vaccine (PCV) into their national infant immu-
nisation protocol. The beneficial effect on overall acute otitis me-
dia (AOM) episodes with CRM197-PCV7 appears to be modest
in healthy, low-risk infants and therefore promoting PCV solely
to reduce AOM for the individual does not seem justified. For
countries that have not yet implemented PCV in the immunisa-
tion protocol and for countries that do not implement a catch-
up vaccination programme for older children up to five years of
age, the question is whether it would be beneficial to administer
the vaccine to older children with a history of AOM. In two trials
in older children with a history of AOM, no beneficial effect of
CRM197-PCV7 on further episodes of AOM was observed (Van
Kempen 2006; Veenhoven 2003), while in a third trial CRM197-
PCV7 administered together with a trivalent influenza vaccine
(CRM197-PCV7/TIV) reduced overall AOM episodes by 57%
during the influenza season, compared to hepatitis B vaccination
(HBV)/placebo vaccination (Jansen 2008). However, the vaccine
efficacy of trivalent influenza vaccine (TIV)/placebo, compared to
HBV/placebo, on overall AOM appeared to be even larger (i.e.
71%), indicating that CRM197-PCV7 after infancy may even
have negative effects on AOM. As such, there is at present no rea-
son to administer the vaccine to older children with a history of
previous AOM episodes in order to protect them against further
AOM episodes. In fact, early vaccination before the first AOM
episode might be required for prevention of middle ear mucosal
damage.
Implications for research
Uncertainty exists nowadays about 1) the effect of widespread im-
plementation of pneumococcal conjugate vaccination on AOM
in everyday practice, 2) the effect of conjugate vaccines that in-
clude more than seven pneumococcal serotypes and 3) the im-
pact of replacement by non-vaccine-type pneumococci or other
otopathogens. Although the beneficial effect of CRM197-PCV7
on all-cause AOM in randomised controlled trials (RCTs) seems
modest, real-world experience gained with widespread CRM197-
PCV7 vaccination in infants after 2000 in the United States sug-
gests that the impact on AOM may be much greater than that
seen in the clinical studies (Taylor 2012). Post-licensure studies,
comparing rates of ambulatory visits related to AOM in the imme-
diate years before and after widespread implementation of routine
CRM197-PCV7 vaccination in children younger than 12 years of
age, have reported a substantial decrease (mean decrease in am-
bulatory visits of 19%). Quickly after the introduction of PCV
in the United States decreases in AOM visits and antibiotic pre-
scriptions were reported in children below two years of age (43%
and 42%, respectively (Zhou 2008)), a decline in the frequency
of otitis media of 17% and 28% in birth cohorts from Tennessee
and upstate New York (Poehling 2007) and an overall downward
trend in otitis media-related health care use in children aged below
six years over the years 2001 to 2011 (Marom 2014). A recent
non-US observational study showed a decline of AOM in Nor-
wegian children aged 12 to 18 months and 18 to 36 months of
14% and 8%, respectively (Magnus 2012). These larger benefits
found in observational studies, compared to the effects reported
in RCTs, might be due to indirect herd effects and may have im-
portant implications for the cost-effectiveness analyses for PCV.
However, the findings of the observational studies must be inter-
preted with caution as variability in baseline incidence, study pop-
ulation, case definition and implementation of AOM treatment
guidelines could have influenced the AOM incidences reported.
For example, results from Boston in the US showed that the de-
cline in uncomplicated AOM, treatment failure and AOM relapse
was at least as large in the 2000 to 2004 period compared to 1996
to 2000 (Sox 2008). Therefore the ’true’ contribution of PCV to
reducing AOM incidence remains uncertain (Sox 2008).
Whether the decline in AOM will continue or wane with time
is relevant and deserves ongoing monitoring. A waning effect in
AOM incidence after implementation of PCV may be explained
by replacement by other otopathogens such as H. influenzae or
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an increase in the proportion of AOM caused by non-CRM197-
PCV7pneumococcal serotypes, including serotypes 3, 6A and19A
(Alonso 2013; Block 2004; Casey 2013; Coker 2010; Couloigner
2012; McEllistrem 2005; Pichichero 2007). As previously men-
tioned, two infant studies found an increase in non-vaccine-type
pneumococcal AOM after administration of CRM197-PCV7, al-
beit not statistically significant, as well as an increase inH. influen-
zae (Eskola 2001; Kilpi 2003). An increase in H. influenzae was
also observed in the post-marketing studies on AOM in the US
(Block 2004; Casey 2004). In addition, the study in older chil-
dren with previous AOM episodes demonstrated an increase in
AOM caused by S. aureus (Veenhoven 2003). In view of the ef-
fects of PCVs on nasopharyngeal carriage of pathogens, awareness
of the possibility of infections caused by replacement pathogens
is warranted. Besides a reduction of nasopharyngeal vaccine-type
serotypes, which is presumed to induce herd effects, replacing
pneumococcal serotypes may not only lead to replacement disease
in vaccines but also in the population. Continuing surveillance of
pneumococcal disease in different settings and geographic loca-
tions is therefore of utmost importance. Currently, several RCTs
with different (newly licensed, multivalent) PCVs administered
during early infancy are ongoing to establish their effects on AOM
(Characteristics of ongoing studies). The results of these studies
may provide a better understanding of the role of PCVs in prevent-
ing all-cause AOM (Hausdorff 2013), including mixed S. pneu-
moniae andH. influenzae infections (Dagan 2013), bacterial-bac-
terial interactions (Van den Bergh 2012) and long-term effects of
shifts in pneumococcal serotypes (Spijkerman 2012).
We emphasise the need for uniform outcome measures (case def-
initions of AOM) and uniform presentation of results to allow
for meta-analysis by pooling the results in future. Reporting of
the total number of AOM episodes in the different study arms,
together with the total follow-up time in person-months, is pre-
ferred. These figures should also be available on the basis of in-
tention-to-treat analysis and not only on the basis of per-protocol
analysis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Black 2000
Methods Randomised - yes, at individual level
Design - standard parallel-group design
Intention-to-treat (ITT) - yes
Follow-up - 6 to 31 months
Participants N - 37,868 healthy infants
Age - 2 months
Setting - 23 medical centres within Northern California Kaiser Permanente (NCKP),
USA
Inclusion criteria - healthy children aged 2 months
Exclusion criteria - children with sickle cell disease, known immunodeficiency, any se-
rious chronic or progressive disease, a history of seizures or a history of either pneumo-
coccal or meningococcal disease
Baseline characteristics - not described
Interventions Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine
(PCV7) or a meningococcus type C conjugate vaccine (MenC) at 2, 4, 6 and 12 to 15
months of age
Tx - PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and
23F conjugated to carrier protein CRM197); N = 18,927 received 1 dose or more of the
vaccine (unclear how many children were included in otitis media analyses)
C - MenC (10 µG of group C oligosaccharide conjugated to carrier protein CRM197)
; N = 18,941 received 1 dose or more of the vaccine (unclear how many children were
included in otitis media analyses)
Additional vaccines - routine childhood vaccines were administered at the recom-
mended ages: diphtheria-tetanus toxoid-whole cell pertussis vaccine (DTwP) or diph-
theria-tetanus toxoid-acellular pertussis vaccine (DTaP); oral poliovirus vaccine or
inactivated poliovirus vaccine; Haemophilus influenzae type B; hepatitis B; measles-
mumps-rubella vaccine; varicella. Initially all participants received a vaccine combining
Haemophilus b conjugate and DTwP into the opposite leg and oral poliovirus vaccine
concurrently. When recommendations changed the protocol was amended to allow ad-
ministration of DTaP and inactivated poliovirus vaccine. Vaccines not given concomi-
tantly were given at least 2 weeks apart from study vaccine
Outcomes Primary outcome - protective efficacy of PCV7 against invasive pneumococcal disease
caused by vaccine serotypes
Secondary outcomes - effect of PCV7 on (a) number of otitis media episodes in fully
vaccinated per-protocol; (b) number of otitis media visits; (c) time to frequent otitis
media (defined as 3 or more episodes in 6 months or 4 or more in 12 months); (d)
number of tympanostomy tubes placements; (e) number of cases of spontaneous draining
ruptured tympanic membranes with culture of a vaccine serotype pneumococcus
Clinical diagnoses of acute otitis media were obtained from computerised data sources
using diagnoses registered by emergency physicians and paediatricians in the NCKP
population. Each clinic visit constituted a new episode unless it was classified as a follow-
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Black 2000 (Continued)
up visit. A visit < 21 days after another otitis media visit was always considered a follow-
up visit. A visit 42 days or more after the most recent otitis media visit was considered a
new episode. Visits occurring between 21 and 42 days, if the appointment was made <
3 days in advance, were considered new episodes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described
Allocation concealment (selection bias) Unclear risk No method of allocation concealment was
described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Indicated to be double-blind study but in-
sufficient details provided to ensure blind-
ing of participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinical diagnoses of AOM were obtained
from computerised data sources using di-
agnoses registered by emergency physicians
and paediatricians (non-trialists)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many children were included
in otitis media analyses
Selective reporting (reporting bias) Unclear risk Study protocol is not available. Otitis me-
dia endpoint (efficacy against otitis media
episodes) is reported as a secondary end-
point
Other bias Low risk Control group was vaccinated against
MenC disease, but meningococci are not a
causative pathogen in otitis media. Study
enrolment was stopped as a result of pre-
specified interim analysis
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Dagan 2001
Methods Randomised - yes, at individual level
Design - standard parallel-group design
Intention-to-treat (ITT) - no, per- protocol analysis
Follow-up - 2 years starting 1 month after complete immunisation
Participants N - 264 healthy infants (261 children were included in clinical follow-up)
Age - 12 to 35 months
Setting - 8 day-care centres in Beer-Sheva, Israel
Inclusion criteria - healthy children aged 12 to 35 months
Exclusion criteria - children that received any vaccine within a 4-week period before, or
were scheduled to receive any vaccine during the 4 weeks after the administration of the
study vaccines, or received immunoglobulin within 8 weeks of study vaccination, known
or suspected impairment of immunologic functions, major congenital malformation or
serious chronic disease, known hypersensitivity to any components of the study vaccine,
previous severe vaccine-associated adverse reaction, previous vaccination with any pneu-
mococcal or meningococcal vaccine, febrile illness (rectal temperature, 38 °C) within 72
h before vaccination
Baseline characteristics - described and balanced (Table 1)
Interventions Children were randomly allocated to either a 9-valent pneumococcal conjugate vaccine
(PCV9) or a meningococcus type C conjugate vaccine (MenC). Children aged 12 to 17
months at time of enrolment received 2 intramuscular injections 2 to 3 months apart
and those 18 to 35 months at time of enrolment received 1 intramuscular injection
Tx - PCV9 (containing the polysaccharides of serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F
and 23F conjugated to carrier protein CRM197); N = 131
C -MenC (10 µG of group C oligosaccharide conjugated to carrier protein CRM197);
N = 130
Additional vaccines - not described
Outcomes Primary outcome - effect of PCV9 on nasopharyngeal carriage of S. pneumoniae of
the serotypes found in the vaccines in general and antibiotic-resistant S. pneumoniae in
particular
Secondary outcomes - effect of PCV9 on parent-reported respiratory infections includ-
ing otitis media
18 encounters were planned for each child during the 2-year follow-up period. During
the first year encounters were planned to take place monthly and during the second year
bimonthly. At each visit the parents were questioned about illness and antibiotic use
since the last visit. Illness episodes were divided into 4 categories:
(1) upper respiratory infections; (2) lower respiratory problems; (3) otitis media; and
(4) other illnesses. Only episodes starting 1 month after complete immunisation were
counted
Notes Participants lost to follow-up during first 12 months - total: 32/261 (12.3%)
Participants lost to follow-up during first 12 months - Tx: 16/131 (12.2%)
Participants lost to follow-up during first 12 months - C: 16/130 (12.3%)
Risk of bias
Bias Authors’ judgement Support for judgement
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Dagan 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described. Block randomisation (n = 6)
stratified by DCC and age
Allocation concealment (selection bias) Low risk Randomisation list provided in a sealed en-
velope by Wyeth-Lederle Vaccines
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Appearance of PCV9 and MenC vaccines
was not similar. 2 nurses not belonging to
the study team injected the vaccines. They
were not allowed reveal the child’s alloca-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Parental interview. A positive report of OM
was defined as an episode
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up rates reported in Table 1. 12%
of children followed up for < 12 months
Selective reporting (reporting bias) Unclear risk Study protocol is not available
Other bias Low risk
Eskola 2001
Methods This trial was part of a study including Kilpi 2003 (FinOM Vaccine Trial). Both Eskola
2001 and Kilpi 2003 used the same control group (hepatitis B vaccine) but a different
treatment group, each with a different type of 7-valent pneumococcal conjugate vaccine.
Eskola 2001 used a PCV7 containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C,
19F and 23F conjugated to carrier protein CRM197, while Kilpi 2003 used a PCV7
containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to
the outer membrane protein complex of N. meningitidis serogroup B
Randomised - yes, at individual level
Design - standard parallel-group design
Intention-to-treat (ITT) - yes, both ITT and per-protocol analysis described
Follow-up - 22 consecutive months (children were followed up to 24 months of age)
Participants N - 1662 healthy infants
Age - 2 months
Setting - 8 study clinics in the communities of Tampere, Kangsala and Nokia, Finland
Inclusion criteria - healthy children aged 2 months
Exclusion criteria - not described
Baseline characteristics - described and balanced (Table 1)
Interventions Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine
(PCV7) or a hepatitis B at 2, 4, 6 and 12 to 15 months of age
Tx - PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and
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Eskola 2001 (Continued)
23F conjugated to carrier protein CRM197); N = 831 (N = 786 completed the follow-
up as specified in the protocol)
C - hepatitis B vaccine (containing 5 µg of recombinant hepatitis B surface protein); N
= 831 (N = 794 completed the follow-up as specified in the protocol)
Additional vaccines - a combination vaccine containing whole-cell DTP and
Haemophilus influenzae type B was given in the child’s opposite thigh at the same visit
as the pneumococcal vaccine at 2, 4 and 6 months of age. In half of the study clinics,
the carrier protein in the DTP andH. influenzae vaccine was CRM197 and in the other
half it was tetanus toxoid. Inactivated poliovirus vaccine was given at 7 months of age
and again at the same time as the fourth dose of the study vaccine at 12 months of age.
Measles-mumps-rubella vaccine was administered at 18 months
Outcomes Primary outcome - effect of PCV7 on the number of acute otitis media (AOM) episodes
due to the pneumococcal serotypes included in the vaccine
Secondary outcomes - effect of PCV7 on the number of all-cause AOM episodes, cul-
ture-confirmed AOM episodes and pathogen-specific AOM episodes, preventing first
and subsequent AOM episodes, number of children with recurrent AOM episodes (de-
fined as 3 or more AOM episodes in last 6 months or 4 or more in the last 12 months),
serious adverse events
All children attended 1 of the study clinics for enrolment at 2months of age and thereafter
at 4, 6, 7, 12, 13, 18 and 24 months. Parents were encouraged to bring their child to the
study clinic for evaluation of symptoms suggesting respiratory infection or AOM. AOM
was diagnosed by otoscopy (visibly abnormal tympanic membrane in terms of colour,
position or mobility, suggesting middle ear effusion) and the presence of at least 1 of
the following symptoms or signs of acute infection: fever, earache, irritability, diarrhoea,
vomiting, acute otorrhoea not caused by otitis externa and other symptoms of respiratory
infection
For the overall and pathogen-specific AOM episodes, a new episode was considered to
have started if at least 30 days had elapsed since the beginning of the previous episode.
For AOM episodes according to serotype, a new episode was considered to have started
if 30 days had elapsed since the beginning of an episode due to the same serotype, or if
any interval had elapsed since the beginning of an episode due to a different serotype. If
more than 1 serotype was recovered from the middle ear fluid at the same time, only 1
episode was considered to have started
Notes Participants lost to follow-up - total: 82/1662 (4.9%) did not complete the follow-up
period according to protocol
Participants lost to follow-up - Tx: 45/831 (5.4%) did not complete the follow-up
period according to protocol
Participants lost to follow-up - C: 37/831 (4.5%) did not complete the follow-up
period according to protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 6 letters corresponding to the 3 treatment
options were randomly allocated to consec-
utive subject identification numbers, using
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Eskola 2001 (Continued)
an allocation of 1:1:1 and a block size of 12
(see Kilpi 2003)
Allocation concealment (selection bias) Low risk Individual treatment assignments were
kept in sealed envelopes until vaccination
(see Kilpi 2003)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of vaccinators who were not otherwise
involved in the trial follow-up. Letter code
was destroyed immediately after vaccina-
tion (see Kilpi 2003)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment of the outcome was done ac-
cording to a strict definition of AOM. As-
sessment was done by other personnel than
those that vaccinated the children (vacci-
nators were not otherwise involved in the
trial follow-up) (see Kilpi 2003)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No reporting of reasons for drop-out and/
or lost to follow-up. Not expected to have
major impact on outcome since 94.6% in
the PCV7 and 95.5% in the control group
completed the follow-up as specified in the
protocol
Selective reporting (reporting bias) Unclear risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov (al-
though uploaded after study end)
Other bias Low risk
Fireman 2003
Methods This study is an extension of Black 2000 (data updated to 1999). Follow-up continued
until children left Northern California Kaiser Permanente (NCKP) or until 20 April
1999, when the study was unblinded and the control group was offered PCV7. For a
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Fireman 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This study is an extension of Black 2000
Method of random sequence generation
not described
Allocation concealment (selection bias) Unclear risk No method of allocation concealment was
described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Indicated to be double-blind study but in-
sufficient details provided to ensure blind-
ing of participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinical diagnoses of AOM were obtained
from computerised data sources using di-
agnoses registered by emergency physicians
and paediatricians (non-trialists)
Incomplete outcome data (attrition bias)
All outcomes
High risk Substantial number of randomised chil-
dren did not stay in the Kaiser Permanente
healthcare database to the end of follow-up
(April 1999), i.e. 27% in the PCV group
and 26% in the control group
Selective reporting (reporting bias) Unclear risk Study protocol is not available but trial
includes all expected outcomes (including
OM visits, frequent OM, tube procedures
and Ab prescriptions)
Other bias Low risk Control group was vaccinated against
MenC disease, but meningococci are not a
causative pathogen in otitis media. Study
enrolment was stopped as a result of pre-
specified interim analysis
Jansen 2008
Methods Randomised - yes, at individual level
Design - standard parallel-group design
Intention-to-treat (ITT) - yes
Follow-up - follow-up started 14 days after the second set of vaccinations and continued
for 6 to 18 months, depending on the year of inclusion
Participants N - 597 children with a previously diagnosed respiratory tract infection (RTI)
Age - 18 to 72 months
Setting - general practitioners (GPs) in the centre of the Netherlands selected children
Inclusion criteria - children aged 18 to 72 months with a previously diagnosed respi-
ratory tract infection (RTI) registered according to the International Classification of
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Primary Care (ICPC), i.e. acute otitis media (AOM); cough (with fever); acute upper
RTI; acute laryngitis/tracheitis; acute bronchitis/bronchiolitis; influenza; pneumonia;
pleurisy/pleural effusion
Exclusion criteria - children with chronic asthma or recurrent wheezing (for longer than
3 months) treated with corticosteroids; craniofacial abnormalities; clinically significant
hypersensitivity to eggs; previous serious adverse reactions to vaccines; previous influenza,
pneumococcal or hepatitis B vaccinations and those with conditions for which these
vaccinations are already recommended, such as chronic cardiac and respiratory conditions
Baseline characteristics - described and balanced (Table 1)
Interventions Children were randomly allocated to either trivalent influenza plus 7-valent pneumo-
coccal conjugate vaccination (TIV/PCV7), trivalent influenza plus placebo vaccination
(TIV/placebo) or hepatitis B virus vaccination plus placebo vaccination (HBV/placebo)
Children received 2 vaccinations 4 to 8 weeks apart in the first year of inclusion and the
first 2 cohorts of children received a subsequent vaccination in the subsequent year
Tx -TIV (strains in the 2003-2004 formulation were H1N1, H3N2 and B/HongKong/
330/01; strains in the 2004-2005 formulation wereH1N1, H3N2 and B/Shanghai/361/
2002; strains in the 2005-2006 formulation included H1N1, H3N2 and B/Shanghai/
361/2002/PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F
and 23F conjugated to carrier protein CRM197); N = 197 (N = 163 completed; 67,867
person-days analysed, 14% missing)
C1 - TIV/placebo (standard diluent (0.9% phosphate buffered NaCl)); N = 187 (N =
148 completed; 60,515 person-days analysed, 20% missing)
C2 - HBV (recombinant HBV vaccine; Engerix-B Junior)/placebo; N = 195 (N = 160
completed; 67,679 person-days analysed, 15% missing)
Additional vaccines - not described
Outcomes Primary outcome - effect of the TIV/PCV7 on febrile RTI, defined as fever (tympanic
temperature 38.0 °C) for at least 2 consecutive days accompanied by 1 or more of the
aforementioned signs or symptoms of RTI with a moderate or severe severity score
Secondary outcomes - effect of the TIV/PCV7 on febrile RTI-related polymerase chain
reaction (PCR)-confirmed influenza, GP visits, antibiotic prescriptions or a physician-
diagnosed episode of AOM
Each parent was instructed to keep a daily diary, recording any clinical signs or symptoms
associated with RTI and to characterise their severity on a scale of 1 (mild) to 3 (severe).
The parent also was instructed to measure the child’s body temperature using a validated
electronic tympanic thermometer. The parent also was asked to record all GP visits due
to their child’s RTI-related complaints. For each such visit, the GP was instructed to
complete a form including information on the diagnosis and possible antibiotic prescrip-
tions
During influenza seasons, the parent was instructed to contact the trial centre for eval-
uation for influenza if the child had fever (tympanic temperature 38.0 °C) for more
than 1 day accompanied by at least 1 RTI-associated sign or symptom of severity score
2. Within 4 days of onset of fever and symptoms, a trained research assistant obtained
a nasopharyngeal swab for viral determination. Each sample was analysed by real-time
PCR for the presence of influenza A and B viruses
Notes Participants lost to follow-up - total: 108/579 (18.7%) completely (n = 41) or partially
(n = 67) lost to follow-up
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Jansen 2008 (Continued)
Participants lost to follow-up - Tx: 34/197 (17.3%) completely (n = 8) or partially (n
= 26) lost to follow-up; 67,867 person-days analysed, 14% missing
Participants lost to follow-up - C1: 39/187 (20.8%) completely (n = 19) or partially
(n = 20) lost to follow-up; 60,515 person-days analysed, 20% missing
Participants lost to follow-up - C2: 35/195 (17.9%) completely (n = 14) or partially
(n = 21) lost to follow-up; 67,679 person-days analysed, 15% missing
2 of the 3 treatment arms received an additional vaccination in the second year of
the study. To evaluate blinding, parents of these cohorts of children were asked which
vaccinations that they thought their child had received just after the vaccinations were
given and at the end of the study. Just after the vaccination, 87% of the parents either
did not know or identified the wrong set of vaccinations; at the end of the study, this
percentage was 80%, indicating successful blinding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described; children were randomly as-
signed in blocks of 3 in a 1:1:1 ratio
Allocation concealment (selection bias) Unclear risk No method of allocation concealment was
described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The injections were administered by non-
blinded research nurses who were not in-
volved in subsequent follow-up and were
instructed to not reveal the intervention al-
location. The treatment group assignments
were not revealed to parents, investigators,
research personnel conducting the follow-
up or health care providers, all of whom re-
mained blinded throughout the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The parents were asked to record all GP
visits due to their child’s RTI-related com-
plaints. For each such visit, the GP was in-
structed to complete a form including in-
formation on the diagnosis and possible an-
tibiotic prescriptions. The treatment group
assignments were not revealed to parents,
investigators, research personnel conduct-
ing the follow-up or health care providers,
all of whom remained blinded throughout
the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Substantial loss to follow-up (< 14% in
both groups)
31Pneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jansen 2008 (Continued)
Selective reporting (reporting bias) Low risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov
Other bias High risk Co-administered with influenza vaccine in
influenza season. Pivotal role of influenza
viruses acknowledged by the authors
Kilpi 2003
Methods This trial was part of a study including Eskola 2001 (FinOMVaccine Trial). Both Eskola
2001 and Kilpi 2003 used the same control group (hepatitis B vaccine) but a different
treatment group, each with a different type of 7-valent pneumococcal conjugate vaccine.
Eskola 2001 used a PCV7 containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C,
19F and 23F conjugated to carrier protein CRM197, while Kilpi 2003 used a PCV7
containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to
the outer membrane protein complex of N. meningitidis serogroup B
Randomised - yes, at individual level
Design - standard parallel-group design
Intention-to-treat (ITT) - no, per-protocol analysis
Follow-up - 22 consecutive months (children were followed up to 24 months of age)
Participants N - 1666 healthy infants
Age - 2 months
Setting - 8 study clinics in the communities of Tampere, Kangsala and Nokia, Finland
Inclusion criteria - healthy children aged 2 months
Exclusion criteria - not described
Baseline characteristics - described and balanced (Table 1)
Interventions Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine
(PCV7) or a hepatitis B at 2, 4, 6 and 12 to 15 months of age. From 3 November
1997 onward, for the children randomised to receive OMPC-PCV7, the fourth dose of
the conjugate vaccine was replaced by a 23-valent pneumococcal polysaccharide vaccine
(PPV-23) that consisted of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14,
15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F (Pneumovax23)
Tx - PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and
23F conjugated to the outer membrane protein complex of N. meningitidis serogroup B
(OMPC)); N = 835 (N = 805 completed the follow-up as specified in the protocol)
C - hepatitis B vaccine (containing 5 µg of recombinant hepatitis B surface protein); N
= 831 (N = 794 completed the follow-up as specified in the protocol)
Additional vaccines - a diphtheria-tetanus toxoids-pertussis vaccine with a whole-cell
pertussis component, combined with aHaemophilus influenzae type b conjugate vaccine
(DTP-Hib), was administered concomitantly with the first 3 doses of the study vaccine
and an inactivated poliovirus vaccine was administered with the fourth dose. In 4 study
clinics, the carrier protein in the DTP-Hib conjugate combination was CRM197 and
in the other 4 it was tetanus toxoid
Outcomes See Eskola 2001
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Notes Participants lost to follow-up - total: 67/1,666 (4.0%) did not complete the follow-
up period according to protocol
Participants lost to follow-up - Tx: 30/835 (3.6%) did not complete the follow-up
period according to protocol
Participants lost to follow-up - C: 37/831 (4.5%) did not complete the follow-up
period according to protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 6 letters corresponding to the 3 treatment
options were randomly allocated to consec-
utive subject identification numbers, using
an allocation of 1:1:1 and a block size of 12
Allocation concealment (selection bias) Low risk Individual treatment assignments were
kept in sealed envelopes until vaccination
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of vaccinators who were not otherwise
involved in the trial follow-up. Letter code
was destroyed immediately after vaccina-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment of the outcome was done ac-
cording to a strict definition of AOM. As-
sessment was done by other personnel than
those who vaccinated the children (vacci-
nators were not otherwise involved in the
trial follow-up)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No reporting of reasons for drop-out and/
or loss to follow-up. Not expected to have a
major impact on outcome since 96.0% in
the PCV7 OMPC and 95.5% in the con-
trol group completed the follow-up as spec-
ified in the protocol
Selective reporting (reporting bias) Unclear risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov (al-
though uploaded after study end)
Other bias Unclear risk Mixed schedule with 187 children boosted
with PPV-23. How was it known that only
the children allocated to PCV7 OMPC
should receive PPV-23 after November
1997?
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O’Brien 2008
Methods The design of this cluster-randomised trial has been described extensively in Moulton
2001, while the findings on invasive pneumococcal disease (main outcome of the trial)
have been published in O’Brien 2003
Randomised - yes, at group level
Design - cluster-randomised design
Intention-to-treat (ITT) - no, per-protocol analysis
Follow-up -depending on time of inclusion,maximumduration of follow-up40months
Participants N - 944 (944 of the 4476 children were randomly selected for chart review. This sample
size was determined by logistic feasibility and expected frequency of healthcare events.
Of these 944 children, 856 were found to have strictly met the chart review criteria)
Age - below 2 years of age
Setting - Navajo and White Mountain Apache region
Inclusion criteria - Navajo and White Mountain Apache children below 2 years of age
Exclusion criteria - no exclusion criteria described
Baseline characteristics - balanced but data not shown
Interventions Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine
(PCV7) or a meningococcus type C conjugate vaccine (MenC). For each of the study
and control vaccines, 3 immunisation schedules were designed according to age of entry
into the trial: 6 weeks to 6 months (3 doses, ideally at 2, 4 and 6 months of age and a
booster at 12 to 15 months of age), 7 months to 11 months (2 doses 1 month apart and
a booster at 12 to 15 months of age) and 12 months to 23 months (2 doses separated by
at least 2 months). Over the course of the trial, the great majority of new enrollees are
in the first group, which is referred to as the primary efficacy cohort
Tx - PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F
conjugated to carrier protein CRM197); N = unknown (N = 424 analysed in primary
efficacy group)
C -MenC (10 µG of group C oligosaccharide conjugated to carrier protein CRM197);
N = unknown (N = 432 analysed in primary efficacy group)
Additional vaccines - not described
Outcomes Primary outcome - effect of PCV7 on clinically diagnosed episodes of OM
Every medical visit made by study children was evaluated through 2 years of age. OM
visits, as documented by the patients’ treating physician, were recorded
A new OM episode was counted if any of the following were recorded as the diagnosis:
OM, AOM, bilateral OM, chronic OM, OM with perforation, otorrhoea, pressure
equalising tube placement, perforated tympanic membrane, serous OM and bullous
myringitis
An episode of AOM was categorised as either AOM or bilateral AOM. An OM episode
was categorised as severe if there were 3 or more OM visits for the episode. A child’s first
medical visit for OM was considered their first episode. OM visits occurring less than
21 days after the immediately prior otitis-related visit and visits noted as a follow-up to
a previous otitis-related visit were counted as follow-up visits, not as OM episodes
Notes Participants lost to follow-up - total: 88/944 (9.3%) not included in primary efficacy
analysis
Participants lost to follow-up - Tx: unknown
Participants lost to follow-up - C: unknown
34Pneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation using
38 independent randomisation units, strat-
ified using 3 blocks of 4 units and 13 blocks
of 2 units
Allocation concealment (selection bias) Low risk 6 labels were assigned to the vaccines (B,
F, H, M, T, U), with 3 labels for PCV7
and 3 for MenC. The grouping of these
codes was known only to a statistician em-
ployed by the manufacturer (who had no
other responsibilities with respect to the
trial other than handling treatment alloca-
tion and randomisation issues. No loss of
clusters
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masked treatment assignment (vaccines
were labelled). In addition, field staff were
blinded as to serotype of the invasive dis-
ease cases and thus did not know which
ones would be likely to be prevented by an
effective vaccine
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Every medical visit made by study chil-
dren was evaluated through 2 years of age.
OM visits, as documented by the patients’
treating physician, were recorded. Treating
physicians were blinded to treatment allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 88 of the 944 children (9.3%) not included
inprimary efficacy analysis; no information
provided on the distribution across treat-
ment groups
Selective reporting (reporting bias) Low risk Study design was described extensively in
Moulton 2001 and O’Brien 2003
Other bias Low risk Study enrolment was stopped as a result of
prespecified interim analysis
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Palmu 2009
Methods This study is an additional analysis of Eskola 2001, which is part of the FinOM Vaccine
Trial and studies the effect of PCV7 containing the polysaccharides of serotypes 4, 6B,
9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197 as compared to a




Outcomes Primary outcome - effect of PCV7 on PCR-positive AOM
The aetiology of AOM attacks was determined by bacterial culture of middle ear fluid
samples obtained by myringotomy. In addition, PCR was performed from the middle
ear fluid samples. Samples with a positive PCR result were reanalysed using Ply-PCR
followed by microwell hybridisation using a Europium-labelled probe
Definitions of 30-day episodes were used in the analysis, for example, a new episode of
PCR-positive AOM was considered to start if 30 days had elapsed since the start of the
previous PCR-positive AOM episode
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk This is an additional analysis of Eskola
2001
6 letters corresponding to the 3 treatment
options were randomly allocated to consec-
utive subject identification numbers, using
an allocation of 1:1:1 and a block size of 12
Allocation concealment (selection bias) Low risk Individual treatment assignments were
kept in sealed envelopes until vaccination
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of vaccinators who were not otherwise
involved in the trial follow-up. Letter code
was destroyed immediately after vaccina-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment of the outcome was done ac-
cording to a strict definition of AOM. As-
sessment was done by other personnel than
those that vaccinated the children (vacci-
nators were not otherwise involved in the
trial follow-up)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many children were lost to
follow-up. In Eskola 2001, 94.6% in the
PCV7 and 95.5% in the control group
36Pneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Palmu 2009 (Continued)
completed the follow-up as specified in the
protocol
Selective reporting (reporting bias) Unclear risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov (al-
though uploaded after study end)
Other bias Low risk
Prymula 2006
Methods Randomised - yes, at individual level
Design - standard parallel-group design
Intention-to-treat (ITT) - yes, both ITT and per-protocol analysis described
Follow-up - efficacy follow-up started on the day of the first dose of study vaccine (for
ITT analysis) or 2 weeks after the third vaccine dose (for the per-protocol analysis) and
continued until 24 to 27 months of age
Participants N - 4968 healthy infants
Age - between 6 weeks and 5 months
Setting - 27 paediatric centres in the Czech Republic and 23 in Slovakia
Inclusion criteria - healthy children aged between 6 weeks and 5 months with no acute
illness
Exclusion criteria - use of any investigational or non-registered drug or vaccine other
than the study vaccines within 30 days preceding the study vaccines’ first dose; previous
vaccination against S. pneumoniae; fever (defined as a rectal temperature of 38 ºC or
higher or temperature by other routes of 37.5 ºC or higher); history of allergic disease
or reactions likely to be exacerbated by any component of the study vaccines; other con-
ditions that might have potentially interfered with the interpretation of study outcomes
according to the investigator
Baseline characteristics - described and balanced (Table 1)
Interventions Childrenwere randomly allocated to either an11-valent pneumococcal conjugate vaccine
(PCV11) or a hepatitis A at the ages of about 3, 4, 5 and 12 to 15 months of age
Tx - PCV11 (containing the polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C,
19F and 23F conjugated to protein D (surface lipoprotein of H. influenzae)); N = 2489
(N = 2455 included in per-protocol cohort for efficacy)
C - hepatitis A vaccine (containing 720 ELISA units of inactivated hepatitis A virus
antigen (strain HM 175)); N = 2479 (N = 2452 included in per-protocol cohort for
efficacy)
Additional vaccines - a concomitant hexavalent diphtheria-tetanus-3-component acel-
lular pertussis-hepatitis B-inactivated poliovirus types 1, 2 and 3 H. influenzae type
b (DTPa-HBV-IPV/Hib) vaccine was offered to all study participants, followed by a
booster dose at age 15 to 18 months
Outcomes Primary outcome - effect of PCV11 on first episode of acute otitis media (AOM) caused
by vaccine pneumococcal serotypes
Secondary outcomes - effect of PCV11 on first episode of AOMcaused by non-typeable
37Pneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Prymula 2006 (Continued)
Haemophilus influenzae
There was no active surveillance. Unscheduled doctor visits could take place any time
during follow-up according to standard local practice (parents consulting their local
paediatrician in case of illness of their child). Parents were advised to consult their
paediatrician if their child was sick, had ear pain or had spontaneous ear discharge.
Children with suspected AOM were immediately referred to ENT surgeons
AOM was defined as either abnormal findings of the tympanic membrane at otoscopy
(i.e. redness, bulging, loss of light reflex) or the presence of middle ear effusion as shown
by simple or pneumatic otoscopy or by microscopy together with at least 2 of the fol-
lowing signs or symptoms: ear pain, ear discharge, hearing loss, fever, lethargy, irritabil-
ity, anorexia, vomiting or diarrhoea. These signs or symptoms had to be present for a
maximum of 14 days
For patients with repeated doctor visits, a new episode of AOM was judged to have
started if more than 30 days had elapsed since the beginning of the previous episode.
Additionally, for categories defined according to bacterial pathogen or serotype, a new
episode was judged to have started if any interval had elapsed since the beginning of an
episode caused by a different bacterial pathogen or serotype
Recurrent AOM was defined as 3 or more AOM episodes in the last 6 months or 4 or
more in the last 12 months
Notes Participants lost to follow-up - total: 61/4968 (1.2%) did not complete the follow-up
period according to protocol
Participants lost to follow-up - Tx: 34/2489 (1.4%) did not complete the follow-up
period according to protocol
Participants lost to follow-up - C: 27/2479 (1.1%) did not complete the follow-up
period according to protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random list
Allocation concealment (selection bias) Low risk Randomisation (1:1) was done with a
study-specific central randomisation sys-
tem via the Internet which, on receipt of
the infant’s initials and birth date, deter-
mined the vaccine number to be used
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Indicated to be double-blinded study.
Sponsor numbered the vaccine supplies. It
was, however, unknown whether the ap-
pearance of the vaccines was similar at the
time of administration
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Visits during efficacy follow-up were ac-
cording to standard local clinical practice.
When AOM was suspected children were
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Prymula 2006 (Continued)
referred to ENT surgeons
Incomplete outcome data (attrition bias)
All outcomes
Low risk No reporting of reasons for drop-out and/
or loss to follow-up. Not expected to have
a major impact on outcome since 98.6%
in the PCV11 and 98.9% in the control
group completed the follow-up as specified
in the protocol
Selective reporting (reporting bias) Low risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov
Other bias Low risk Study enrolment was stopped as a result of
prespecified interim analysis
Van Kempen 2006
Methods This study was performed in parallel with Veenhoven 2003, but analysed separately due
to differences in study population
Randomised - yes, at individual level
Design - standard parallel-group design
Intention-to-treat (ITT) - unclear
Follow-up - 26 months
Participants N - 74 children with a history of frequent acute otitis media (AOM)
Age - between 1 and 7 years
Setting - ENT department of the Ghent University Hospital in Belgium
Inclusion criteria - children aged 1 to 7 years with a history of frequent AOM defined
as at least 2 separate clinically diagnosed AOM episodes in the past year
Exclusion criteria - children with any underlying illnesses including immunocompro-
mising conditions other than partial serum IgA and IgG2 deficiencies, craniofacial ab-
normalities, previous pneumococcal vaccination or documented hypersensitivity to any
of the vaccine components
Baseline characteristics - described and balanced (Table 1)
Interventions Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine
(PCV7) or a hepatitis A vaccine. Children aged 12 to 24months received 2 intramuscular
injections with a 1-month interval and those aged over 2 years received 1 intramuscu-
lar injection. Those allocated to PCV7 received an additional 23-valent pneumococcal
polysaccharide vaccination (PPSV-23) respectively at 6 months (in children aged 12 to
24 months) and 7 months (in those aged above 2 years) later
Tx - PCV7 (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F
conjugated to the carrier protein CRM197)/PPSV23 (containing polysaccharides of the
serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A,
20, 22F, 23F and 33F); N = 38 (N = 35 completed the vaccination scheme)
C - hepatitis A vaccine (containing 720 units of inactivated hepatitis A virus); N = 36
(N = 33 completed the vaccination scheme)
Additional vaccines - not described
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Outcomes Primary outcome - effect of PCV7/PPSV23 on the number of AOM episodes during
18 months follow-up
Secondary outcomes - effect of PCV7/PPSV23 on immunogenicity; nasopharyngeal
carriage of conjugate vaccine related serotypes; and antibiotic-resistant pneumococci
At scheduled hospital visits at 7, 14, 20 and 26 months after randomisation, a medical
history was taken, antibiotic usage noted and an otomicroscopic examination performed
When, at least 1 month following complete vaccination, a new AOM episode was sus-
pected, parents were asked to bring their sick child within 24 hours to the study centre
for otoscopic diagnosis. In case of all other AOM episodes during follow-up, participants
were allowed to visit the study centre, their family physician or a paediatrician who was
asked to report otoscopic findings, diagnosis and treatment on an AOM registration
form
AOM was defined by an abnormal tympanic membrane on otomicroscopy (red, dull or
bulging); plus at least 1 of the following symptoms or signs of acute infection: earache,
acute otorrhoea, fever (> 38.5 °C rectally) or irritability
Notes Participants lost to follow-up - total: 6/74 (8.1%) did not complete the follow-up
period according to protocol
Participants lost to follow-up - Tx: 3/38 (7.9%) did not complete the follow-up period
according to protocol
Participants lost to follow-up - C: 3/36 (8.3%) did not complete the follow-up period
according to protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described, randomisation stratified ac-
cording to age (12 to 24 months versus
25 to 84 months) and number of previous
AOM episodes per year (2 to 3 versus 4 or
more episodes)
Allocation concealment (selection bias) Low risk 2 study nurses immunised all children ac-
cording to a randomisation list provided
to them in a sealed envelope by a third
party (the Julius Center for Health Sci-
ences, Utrecht, The Netherlands)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The nurses that vaccinated children were
not allowed to reveal the child’s allocation
to either the study team or the parents
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk When a new AOM episode was suspected,
parents were asked to bring their sick child
within 24 hours to the study centre for
otoscopic diagnosis. In case of all other
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AOM episodes during follow-up, partici-
pants were allowed to visit the study cen-
tre, their family physician or a paediatrician
whowas asked to report otoscopic findings,
diagnosis and treatment on an AOM reg-
istration form
Incomplete outcome data (attrition bias)
All outcomes
Low risk In total 6 of the 74 children (8.1%) did not
complete the follow-up period according to
protocol (equally distributed across groups)
. Reasons for withdrawals are described in
the Results section of the article
Selective reporting (reporting bias) Unclear risk No study protocol available
Other bias Low risk
Veenhoven 2003
Methods Randomised - yes, at individual level
Design - standard parallel-group design
Intention-to-treat (ITT) - yes
Follow-up - 18 months, starting 1 month after completion of the vaccination scheme
Participants N - 383 children with a history of frequent acute otitis media (AOM)
Age - between 1 and 7 years
Setting - a general hospital (SpaarneHospital, Haarlem) and a tertiary care hospital (Wil-
helmina Children’s Hospital of the University Medical Centre Utrecht) in the Nether-
lands
Inclusion criteria - children aged 1 to 7 years with a history of frequent AOMdefined as
2 or more AOM episodes in the year before study entry. The number of previous AOM
episodes was based on parental report and on clinical confirmation of the diagnosis by a
physician
Exclusion criteria - children with immunodeficiency, cystic fibrosis, immotile cilia syn-
drome, craniofacial abnormalities, chromosomal abnormalities such asDown’s syndrome
and severe adverse events during previous vaccinations
Baseline characteristics - described and balanced (Table 1)
Interventions Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine
(PCV7) followed by a 23-valent pneumococcal polysaccharide vaccination (PPSV23) or
a hepatitis A or B vaccine
Children aged 12 to 24 months in the pneumococcal vaccination group received PCV7
twice with a 1-month interval followed 6 months later by PPSV23. The control vaccine
group received 3 hepatitis B vaccinations according to a similar time schedule
Children aged 25 to 84 months in the pneumococcal vaccine group received 1 dose
of PCV7 followed 7 months later by PPSV23. The control group received hepatitis A
vaccine twice
Tx - PCV7 (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F
conjugated to the carrier protein CRM197)/PPSV23 (containing polysaccharides of the
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serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A,
20, 22F, 23F and 33F); N = 190 (N = 190 included in ITT analysis)
C - hepatitis A vaccine (Havrix) or hepatitis B vaccine (Engerix-B); N = 193 (N = 193
included in ITT analysis)
Additional vaccines - not described.
Outcomes Primary outcome - effect of PCV7/PPSV23 on the number of clinical episodes of AOM
during 18 months follow-up
Secondary outcomes - effect of PCV7/PPSV23 on the number of AOM episodes due
to the 7 pneumococcal serotypes included in the PCV7 vaccine and nasopharyngeal
carriage of conjugate vaccine serotypes
Parentswere instructed to visit the study clinics or their family physician, otolaryngologist
or paediatrician to assess symptoms suggesting AOM. Physicians registered signs and
symptoms of every AOM episode on standard registration forms and were unaware of
treatment allocation. AOM was defined according to the guideline issued by the Dutch
College of General Practitioners, i.e. presence of an abnormal tympanic membrane on
otoscopy (red, dull or bulging), or otorrhoea and at least 1 of these signs or symptoms
of acute infection: acute earache, new-onset otorrhoea, irritability or fever greater than
38.5 ºC rectally or 38.0 ºC axillary
Notes Participants lost to follow-up - total: 1/383 (0.3%); all children included in ITT
analysis
Participants lost to follow-up - Tx: 0/190 (0%)
Participants lost to follow-up - C: 1/193(0.5%)
Performed in parallel with the study of Van Kempen 2006, but analysed separately due
to differences in study population
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers that identified
the vaccine scheme, randomisation strati-
fied according to age (12 to 24 months ver-
sus 25 to 84 months) and number of previ-
ous AOM episodes per year (2 to 3 versus
4 or more episodes)
Allocation concealment (selection bias) Unclear risk No method of allocation concealment was
described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Vaccine was administered to the child by a
study nurse, so that parents and physicians
were unaware of treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents were instructed to visit the study
clinics or their family physician, otolaryn-
gologist or paediatrician to assess symp-
toms suggesting AOM. Physicians regis-
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tered signs and symptoms of every AOM
episode on standard registration forms
and were unaware of treatment allocation.
AOM was defined according to the guide-
line issued by theDutch College of General
Practitioners
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised children were included in
ITT analysis
Selective reporting (reporting bias) Unclear risk No study protocol available
Other bias Low risk
Ab: antibiotics; AOM: acute otitismedia; C: control; DCC: day-care centre;DTaP: diphtheria-tetanus toxoid-acellular pertussis vaccine;
DTP: diphtheria-tetanus toxoid-pertussis vaccine; DTwP: diphtheria-tetanus toxoid-whole cell pertussis vaccine; ENT: ear, nose and
throat; IgA: immunoglobulin A; IgG: immunoglobulin G; GP: general practitioner; ITT: intention-to-treat; NaCl: sodium chloride;
OM: otitis media; PCR: polymerase chain reaction; PCV: pneumococcal conjugate vaccine; PPV: pneumococcal polysaccharide
vaccine; RTI: respiratory tract infection; TIV: trivalent influenza vaccine; Tx: treatment
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gisselsson Solen 2011 No control vaccination. As such, parents were not blinded to treatment allocation (children received either
PCV or no vaccination). However, for outcome assessment, parents were instructed to visit the ENT
department whenever they suspected an episode of AOM. Parental threshold to consult ENT may be lower
in children allocated to control treatment (no vaccination) than in those allocated to PCV, which may have
introduced (detection) bias
Jokinen 2012 Re-analysis of the Eskola 2001 study without new outcome data that could be used for our review
Le 2007 RCT studying the effect of PCV on OME
Roy 2011 RCT studying the effect of PCV on suppurative otitis media (abstract of conference meeting)
AOM: acute otitis media
ENT: ear, nose and throat
OME: otitis media with effusion
PCV: pneumococcal conjugate vaccine
RCT: randomised controlled trial
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NCT00466947
Trial name or title ’COMPAS: Phase III, Double-blind, Randomized Study to Demonstrate Efficacy of GSK Biologicals’ Pneu-
mococcal Conjugate Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis
Media (AOM)’
Methods Phase III, double-blind, randomised study
Participants Healthy children aged 6 to 16 weeks
Interventions Group A: pneumococcal conjugate vaccine GSK1024850A 4 doses, hepatitis A vaccine 2 doses, DTaP-IPV/
Hib vaccine 1 dose Group B: hepatitis A vaccine 3 doses, hepatitis B vaccine 3 doses, DTaP-IPV/Hib vaccine
4 doses
Outcomes Primary outcome: occurrence of likely bacterial community-acquired pneumonia (CAP) cases
Secondary outcomes include occurrence of clinically confirmed acute otitis media (AOM) cases (in a subset)
, occurrence of bacteriologically confirmed AOM cases (B-AOM) caused by any bacterial pathogen (in a
subset), bacteriologically confirmed AOM cases (B-AOM) caused by vaccine serotypes, cross-reactive and
other pneumococcal serotypes (in a subset)
Starting date June 2007; study complete date: June 2011
Contact information GSK Clinical Trials Call Centre
Notes NCT00466947
NCT00861380
Trial name or title ’Evaluation of Effectiveness ofGSKBiologicals’ Pneumococcal Conjugate Vaccine 1024850AAgainst Invasive
Disease (FinIP)’
Methods Cluster-randomised, double-blind trial
Participants Healthy children aged younger than 19 months
Interventions Infants aged younger than 7months at the first vaccination received either a 3+1 or a 2+1 vaccination schedule,
children aged 7 to 11 months received a 2+1 schedule and those 12 to 18 months of age received a 2-dose
schedule. Children received PD-CV10 in 52 clusters or hepatitis vaccines as control in 26 clusters
Outcomes Primary outcome: occurrence of culture-confirmed pneumococcal invasive diseases due to any of the vaccine-
related pneumococcal serotypes
Secondary outcomes include occurrence of tympanostomy tube placements, occurrence of upper and lower
respiratory tract infections, including AOM (in a subset of vaccinated subjects in Turku area)
Starting date March 2009; study complete date: January 2012
Contact information GSK Clinical Trials Call Centre
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Notes NCT00861380; published papers: effect PD-CV10 on primary outcome (Palmu 2013a) and secondary
outcome, i.e. outpatient antimicrobial purchases (Palmu 2013b)
NCT01174849
Trial name or title ’A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence
or Alone in High-risk Indigenous Infants (PREV-IX COMBO): Immunogenicity, Carriage and Otitis Media
Outcomes’
Methods Open-label, randomised study
Participants Indigenous infants 4 to 6 weeks of age
Interventions 3 doses of either PCV13 or PD-CV10 versus an early schedule of a combination of 3 doses of PD-CV10 and
1 dose of PCV13
Outcomes Primary outcome: immunogenicity
Secondary outcomes: nasopharyngeal carriage, otitis media
Starting date August 2011
Contact information Amanda J Leach, PhD; Menzies School of Health Research, Darwin, Northern Territory, Australia, 0810
Notes NCT01174849
NCT01545375
Trial name or title ’Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children: Study to Determine Protective
Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in
Healthy Infants’
Methods Double-blind, placebo-controlled, randomised study
Participants A healthy American Indian infant between and including 6 and 12 weeks (42 to 90 days) of age at the time
of the first vaccination
Interventions GSK2189242A vaccine versus placebo co-administration of PCV13 and Hib-CV. Hib-CV will be given as
study vaccine for infants of the immuno/reacto subgroup; for the other infants, this vaccine will be given as
part of the routine vaccination schedule
Outcomes Primary outcome: occurrence of any clinical AOMepisodes diagnosed and verified against American Academy
of Pediatrics (AAP) criteria
Secondary outcomes include occurrence of any healthcare provider-diagnosed clinical AOM, occurrence of
any clinical AOM episodes diagnosed and verified against modified AAP criteria, occurrence of any recurrent
AOM (at least 3 episodes in 6 months or at least 4 episodes in 12 months)
Starting date May 2012
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NCT01545375 (Continued)
Contact information GSK Clinical Trials Call Center
Notes NCT01545375
NCT01735084
Trial name or title ’Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Con-
trolled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive andMucosal Infections’
Methods Single-blind (outcomes assessor), randomised study
Participants Australian indigenous infants who were participants in PREV-IX COMBO trial of primary course pneumo-
coccal conjugate vaccines, age at least 2 months post final dose of primary course
Interventions PCV13 versus PD-CV10
Outcomes Primary outcome: immune response
Secondary outcomes: nasopharyngeal carriage, any otitis media, episodes of respiratory illness and acute otitis
media
Starting date December 2012
Contact information Amanda J Leach, PhD; Menzies School of Health Research, Darwin, Northern Territory, Australia, 0810
Notes NCT01735084
AAP: American Academy of Pediatrics
AOM: acute otitis media
DTaP-IPV/Hib: diphtheria-tetanus toxoid-acellular pertussis-inactivated polio-haemophilus influenzae type B vaccine
Hib-CV: haemophilus influenzae type B conjugate vaccine
A D D I T I O N A L T A B L E S
Table 1. The effect of pneumococcal conjugate vaccination on all-cause acute otitis media episodes
Intention-to-treat Per-protocol










in risk (95% CI)
Treatment Control Treatment Control
PCV administered in early infancy
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6% (4 to 9)







7% (4 to 10)
7% (4 to 9)
Eskola 2001 - - - 1.16 1.24 -0.08 ~ 6% (-4 to 16)
Kilpi 2003 - - - - - - -1% (-12 to 10)
Prymula 2006 - - - 0.08 0.13 -0.04 ~ 34% (21 to 44)
O’Brien 2008
∗
1.4 1.4 -5% (-25 to 12)
#
1.3 1.3 0.0 (-0.13 to 0.14) 0% (-21 to 17)
PCV administered at a later age
Dagan 2001 - - - 0.66 0.79 -0.14 (-0.29 to 0.
02)
17% (-2 to 33)
Veenhoven
2003
- - -25% (-57 to 1) 1.1 0.83 0.27 ~ -29% (-62 to -2)
Van Kempen
2006
- - - 0.78 0.67 0.11 ~ -16% (-96 to 31)
Jansen 2008 - - - - - - 57% (6 to 80)ˆ
CI: confidence interval; HBV: hepatitis B vaccine; PCV: pneumococcal conjugate vaccine; TIV: trivalent influenza vaccine; VE: vaccine
efficacy.
∗Cluster-randomised trial.
#Defined as primary efficacy analysis. Analysis not entirely according to intention-to-treat principle as 88/944 children were not
included in analysis because of not meeting strict chart review criteria.
ˆIndex group: TIV/PCV7, control: HBV/placebo; VE TIV/placebo versus HBV/placebo: 71% (95% 30% to 88%), i.e. larger VE TIV/
placebo versus HBV/placebo then TIV/PCV7 versus HBV/placebo.
~ 95% CI could not be calculated as person-time across treatment groups was not reported.
Note: negative values for VE expressed as relative reduction in risk represent an increase in the risk for AOM.
Table 2. The effect of pneumococcal conjugate vaccination on pneumococcal acute otitis media
Intention-to-treat Per-protocol

























PCV administered in infancy
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- 64% (-34 to
90)
- - - - - -
PCV administered at a later age
Dagan 2001 - - - - - - - -
Veenhoven
2003
- - - - 34% P = 0.
22
52% P = 0.
21





- - - - - - - -
Jansen 2008 - - - - - - - -
VE: vaccine efficacy; PCV: pneumococcal conjugate vaccine; MEF: middle ear fluid.
∗Cluster-randomised trial.
#MEF collected from spontaneous draining ears; in the other studies MEF was routinely collected during AOM episodes through
paracentesis.
ˆAdditional analysis of Eskola 2001 including pneumococcal AOM by a positive culture or PCR.
Note: negative values represent an increase in the risk of AOM.
Table 3. The effect of pneumococcal conjugate vaccination on recurrent acute otitis media
Intention-to-treat Per-protocol
VE expressed as relative reduction in risk (95%
CI)
VE expressed as relative reduction in risk (95%
CI)
PCV administered in infancy
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Table 3. The effect of pneumococcal conjugate vaccination on recurrent acute otitis media (Continued)
Black 2000
Fireman 2003
9% (4 to 14)
10% (7 to 13)
9% (3 to 15)
-
Eskola 2001 9% (-12 to 27) 16% (-6 to 35)
Kilpi 2003 - -
Prymula 2006 - 56% (-2 to 81)
O’Brien 2008∗ - -
PCV administered at a later age
Dagan 2001 - -
Veenhoven 2003 - -
Van Kempen 2006 - -
Jansen 2008 - -
PCV: pneumococcal conjugate vaccine; VE: vaccine efficacy.
∗Cluster-randomised trial.
Note: negative values represent an increase in the risk of recurrent AOM.
A P P E N D I C E S
Appendix 1. Previous search
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, issue 2), which contains the
Cochrane Acute Respiratory Infections Group’s Specialised Register; MEDLINE (January 1995 to November 2007); and EMBASE
(January 1995 to November 2007).
We used the following search strategy for searching MEDLINE and CENTRAL and modified terms for searching EMBASE.
MEDLINE
#1 explode ‘bacterial-vaccine’ / all subheadings
#2 explode ‘bacterial AND vaccine’ / all subheadings
#3 explode ‘Pneumococcus-vaccine’ / all subheadings
#4 pneumococc* near immunity*
#5 pneumococc* near vaccin*
#6 #1 or #2 or #3 or #4 or #5
#7 explode ‘otitis media’ / all subheadings
#8 (otitis media in ti) or (otitis media in ab)
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#9 #7 or #8
#10 #6 or #9
#11 explode ‘randomised-controlled-trial’ / all subheadings
#12 explode ‘controlled-study’ / all subheadings
#13 explode ‘randomisation’ / all subheadings
#14 explode ‘single-blind-procedure’ / all subheadings
#15 explode ‘double-blind-procedure’ / all subheadings
#16 explode ‘crossover-procedure’ / all subheadings
#17 explode ‘phase-3-clinical-trial’ / all subheadings
#18 (control* near trial*) in ti)
#19 (control* near trial*) in ab)
#20 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in ti)
#21 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in ab)
#22 random* near ((allocat* or assign*) in ti)
#23 random* near ((alsocat* or assign*) in ab)
#24 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #10 and #24
Appendix 2. Embase.com search strategy
#14. #9 AND #13
#13. #10 OR #11 OR #12
#12. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR ’cross-over’:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti
#11. ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#10. ’randomized controlled trial’/exp
#9. #3 AND #8
#8. #4 OR #5 OR #6 OR #7
#7. pcv*:ab,ti
#6. (pneumococc* NEAR/5 (vaccin* OR conjugat* OR immuni*)):ab,ti
#5. ’bacterial vaccine’/de
#4. ’pneumococcus vaccine’/de
#3. #1 OR #2
#2. ’otitis media’:ab,ti OR aom:ab,ti
#1. ’otitis media’/exp
Appendix 3. CINAHL (Ebsco) search strategy
S22 S11 and S20
S21 S11 and S20
S20 S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19
S19 (MH “Quantitative Studies”)
S18 (MH “Placebos”)
S17 TI placebo* OR AB placebo*
S16 TI random* OR AB random*
S15 TI ( singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*
) OR AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl*
mask* )
S14 TI clinic* trial* OR AB clinic* trial*
S13 PT clinical trial
S12 (MH “Clinical Trials+”)
S11 S3 and S10
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S10 S4 or S5 or S6 or S7 or S8 or S9
S9 TI pcv* OR AB pcv*
S8 TI pneumococc* N5 immuni* OR AB pneumococc* N5 immuni*
S7 TI pneumococc* N5 conjugat* OR AB pneumococc* N5 conjugat*
S6 TI pneumococc* N5 vaccin* OR AB pneumococc* N5 vaccin*
S5 (MH “Bacterial Vaccines”)
S4 (MH “Pneumococcal Vaccine”)
S3 S1 or S2
S2 TI ( otitis media or aom ) OR AB ( otitis media or aom )
S1 (MH “Otitis Media+”)
Appendix 4. LILACS (Brieme) search strategy
(mh:“otitis media” OR “otitis media” OR “Otite Média” OR mh:c09.218.705.663* OR aom) AND (mh:“Pneumococcal Vaccines”
OR “Vacunas Neumococicas” OR “Vacinas Pneumocócicas” OR mh:“Vaccines, Conjugate” OR “Vacunas Conjugadas” OR “Vacinas
Conjugadas” OR mh:“Bacterial Vaccines” OR “Vacunas Bacterianas” OR “Vacinas Bacterianas” OR “pneumococcal vaccine” OR
“pneumococcal vaccines” OR “conjugate vaccines” OR “conjugate vaccine” OR pcv*) AND db:(“LILACS”) AND type˙of˙study:
(“clinical˙trials”)
Appendix 5. Web of Science (Thomson ISI) search strategy
# 6 40 #4 AND #3
Refined by: Publication Years=( 2011 OR 2012 OR 2013 )
Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years
# 5 205 #4 AND #3
Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years
# 4 1,334,537 Topic=(random* or placebo* or allocat* or crossover* or “cross over” or ((doubl* or singl*) NEAR/1 (blind* or
mask*))) OR Title=(trial)
Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years
# 3 1,095 #2 AND #1
Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years
# 2 11,997 Topic=(pneumococc* NEAR/5 (vaccin* or conjugat* or immuni*)) OR Topic=(pcv*)
Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years
# 1 17,113 TS=(“otitis media” or aom)
Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years
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WH A T ’ S N E W
Last assessed as up-to-date: 3 December 2013.
Date Event Description
21 February 2014 New citation required and conclusions have changed With this update, more precise information on the ef-
fect of PCV7 for the prevention of otitis media has be-
come available. We judged the quality of the evidence
for PCV7 in both early infancy and older children to be
high and further research is very unlikely to change our
confidence in the estimate of effect
Based on current evidence of the effects of pneumococ-
cal conjugate vaccines (PCVs) for preventing acute otitis
media (AOM), the licensed 7-valent PCV has modest
beneficial effects in healthy infants with a low baseline
risk of AOM. Administering PCV7 in high-risk infants,
after early infancy and in older children with a history of
AOM appears to have no benefit in preventing further
episodes
Currently, several randomised controlled trials (RCTs)
, with different (newly licensed, multivalent) PCVs ad-
ministered during early infancy, are ongoing to establish
their effects on AOM. The results of these studies may
provide a better understanding of the role of the newly
licensed, multivalent PCVs in preventing AOM. Also
the impact of the carrier protein D, as used in certain
pneumococcal vaccines for AOM, needs to be further
established
3 December 2013 New search has been performed Three new review authors joined the team to update
this review
With the updated search (November 2007 to Decem-
ber 2013) we retrieved 171 records. Removing dupli-
cates left 165 records. After screening titles and abstracts,
three new publications remained for inclusion (Palmu
2009; Prymula 2006; Van Kempen 2006). One study
was an additional analysis of the previously included
Eskola 2001 study.
We identified five ’ongoing’ RCTs (NCT00466947;
NCT00861380; NCT01545375; NCT01735084;
NCT01174849).
The 11 included studies in this review concerned nine
RCTs in total: (1) Black 2000/Fireman 2003; (2) Dagan
2001; (3) Eskola 2001/Palmu 2009; (4) Kilpi 2003; (5)
Prymula 2006; (6) Van Kempen 2006; (7) Veenhoven
2003; (8) Jansen 2008 and (9) O’Brien 2008. Five trials
(Black 2000/Fireman 2003; Eskola 2001/Palmu 2009;
Kilpi 2003; O’Brien 2008; Prymula 2006) (n = 47,108)
included healthy infants and studied the effect of PCV
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(Continued)
administered in early infancy on otitis media (OM),
while the other four trials (n = 1318) (Dagan 2001;
Jansen 2008; Van Kempen 2006; Veenhoven 2003) as-
sessed the effects of PCV administered at a later age on
OM in either healthy infants (Dagan 2001) or in chil-
drenwith a knownhistory of respiratory disease, includ-
ing OM (Jansen 2008; Van Kempen 2006; Veenhoven
2003).
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 2, 2002
Date Event Description
29 April 2008 New citation required but conclusions have not
changed
New review authors
28 April 2008 Amended Converted to new review format
15 November 2007 New search has been performed Searches conducted
26 November 2003 New citation required and conclusions have changed Substantive amendment
29 June 2003 New search has been performed Searches conducted
19 August 2000 New search has been performed Searches conducted
C O N T R I B U T I O N S O F A U T H O R S
ACF, RPV co-ordinated the review.
ACF, RPV, CWB were involved in data collection.
ACF and RPV performed ’Risk of bias’ assessment and analysis of data.
All review authors (ACF, ES, EH, RPV, CWB, AS, RD) were involved in designing and writing the review and interpreting the data.
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N O T E S
The focus in research has shifted from the use of pneumococcal polysaccharide vaccines (PPVs) to pneumococcal conjugate vaccines
(PCVs) in children and the role of PPVs in the prevention of AOM in children has merely been assessed following PCVs and no longer
as a primary intervention. Therefore, the focus of the current review has shifted from the effect of PPVs to the effect of PCVs on acute
otitis media. No further attention will be paid to the effect of PPVs, which were described in prior versions of this review (Straetemans
2003).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
AcuteDisease;OtitisMedia [microbiology; ∗prevention&control]; Pneumococcal Vaccines [∗therapeutic use]; RandomizedControlled
Trials as Topic; Vaccines, Conjugate [therapeutic use]
MeSH check words
Child; Child, Preschool; Humans; Infant
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